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ABSTRACT
Nanoemulsions Within Liposomes for Cytosolic Drug Delivery to
Multidrug-Resistant Cancer Cells
Jacob Brian Williams
Department of Chemical Engineering, BYU
Doctor of Philosophy
Cancer cells that survive chemotherapy treatment often develop resistance to the
administered chemotherapeutics, as well as to many other types of drugs, because the cancer
cells increase their production of efflux pumps in the cell. This undesired phenomenon of
resistance to cancer drugs is known as multidrug resistance. This work uses a novel drug carrier,
called an eLiposome, to achieve cytosolic drug delivery to kill multidrug-resistant cancer cells.
An eLiposome consists of a perfluoropentane (PFC5) emulsion droplet inside of a
liposome. Folate attached to the eLiposome facilitates uptake into the cell. The PFC5 droplet is
metastable at body temperature, but will rupture the liposome as the droplet expands during
vaporization, and will release any drugs encapsulated inside of the liposome directly to the cell
cytosol.
Laser and ultrasound were examined as triggers to initiate the vaporization of the PFC5
droplet and actuate the release of doxorubicin (Dox) from folated eLiposomes containing Dox
(feLD). Gold nanorods (GNRs) were synthesized and transferred to PFC5 droplets. Although
GNRs are efficient at converting irradiated laser light to heat, no vaporization of the PFC5
droplets was observed when irradiated with laser light. Further investigation into the energy
required for vaporization of PFC5 droplets revealed that there are currently no portable and
wearable lasers available to provide enough energy to vaporize PFC5 droplets.
Two seconds of ultrasound can release 78% of encapsulated Dox from feLD. Doxsensitive KB-3-1 cells and Dox-resistant KB-V1 cells treated with feLD (without ultrasound) had
cell viabilities of 33% and 60%, respectively. Ultrasound had negligible additional effect on the
cell viability of KB-3-1 and KB-V1 cells treated with feLD (33% and 53%, respectively). We
hypothesized that the Dox fiber formed during the loading of Dox into the eLiposome is a site
for heterogeneous nucleation once the feLD is endocytosed by the cell, and vaporization and
drug release occurs with or without ultrasound.
Blocking the efflux pumps with verapamil decreases the rate at which Dox is exported
from multidrug-resistant cells. When verapamil is co-delivered with feLD, the cell viability of
KB-3-1 and KB-V1 cells decreases to 29% and 25%, respectively; thereby reversing the
multidrug resistance possessed by KB-V1 cells. The delivery of doxorubicin inside of folated
eLiposomes with an efflux pump blocker is a novel way to kill multidrug-resistant cancer cells as
effectively as non-resistant cancer cells independent of lasers or ultrasound.
Keywords: multidrug resistance, liposome, drug delivery, doxorubicin, verapamil, co-delivery,
vaporization, emulsion, ultrasound, gold nanorod, laser, eLiposome
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1

INTRODUCTION

Cancer is the 2nd leading cause of death in the United States, close behind heart disease;
however, it is the leading cause of death in the United States for individuals between ages 40-79
[1]. It is estimated that there will be 595,690 cancer related deaths and 1,685,210 new cases of
cancer in the United States in 2016 [1]. Treating cancer is a national priority.
Cancer cells are characterized by rapid division and uncontrolled growth that eventually
inhibits other functions of the body. Current methods for treating cancer include surgery,
radiation, or chemotherapy, as well as combinations of these treatments [2]. Chemotherapy is the
delivery of cancer drugs at a high enough dosage to kill the cancer cells while not killing the
patient. Unfortunately, no cancer drug in current use perfectly distinguishes between normal and
healthy cells, so significant side effects, such as hair loss, nausea, weight loss, and fatigue, are
associated with chemotherapy treatments [3].
In 2000, Hanahan and Weinberg proposed six hallmarks of cancer: sustaining
proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative
immortality, inducing angiogenesis, and activating invasion and metastasis [4]. In 2011, they
noted four more emerging hallmarks of cancer: deregulating cellular energetics, avoiding
immune destruction, genome instability and mutation, and tumor promoting inflammation [5].
Drugs can target cancer cells by preferentially targeting cells with one or more of the hallmarks
described by Hanahan and Weinberg.
1

Targeted drug delivery helps cancer drugs preferentially target tumor cells over healthy
cells and decreases the negative side effects associated with chemotherapy. It allows for a higher
concentration of drug to accumulate at the tumor site (an abnormal growth of cancerous tissue),
and a lower concentration of drug to accumulate around healthy cells. One common method to
target cancer cells is to attach a ligand to the drug or drug carrier that corresponds to membrane
receptors that are upregulated in cancer cells due to the hallmarks explained above. For example,
the folate receptor is upregulated in over 1/3 of cancer cells [6] and is associated with sustaining
proliferative signaling.
Another method to minimize the negative side effects of chemotherapy, as well as
increase drug efficacy, is to have the drug remain inactive until it reaches the tumor. This can be
done by either developing a prodrug (an inactive compound that becomes active after it is
chemically altered) or by encapsulating the drug inside of or attached to a drug delivery vehicle
and only activating or releasing the drug at the tumor site. Drugs are released, or prodrugs are
chemically changed from inactive to active, when exposed to specific stimuli; thus the drug
actions are localized to specific sites in the body. Triggered drug release from a drug delivery
vehicle can be actuated by internal mechanisms (i.e., changes in pH [7] or temperature [8]) or by
external stimuli (i.e., ultrasound [9], near-infrared light [10], or magnetic fields [11]).
Delivering drugs directly to the tumor site will decrease the negative side effects of
chemotherapy, but there is another problem associated with chemotherapy. It is the acquired
resistance to chemotherapeutics. More specifically, over time the cancer can often become
resistant to both the initially administered cancer drug as well as to unrelated cancer drugs—a
phenomenon known as multidrug resistance. Resistance to the chemotherapeutics limits the
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treatment methods available to the patient because a higher or more frequent dosage is required
for efficacy, often resulting in a required dosage that exceeds the lethal level.
One of the established mechanisms for multidrug resistance is an increased number of
efflux pumps [12-15] which increase the rate at which undesired compounds inside of the cell
(such as cancer drugs) are pumped out of the cell. In conventional drug delivery, cancer drugs
accumulate at the tumor site and diffuse into the cancer cells. The rate of accumulation inside of
resistant cancer cells is much lower than the rate of accumulation inside of drug-sensitive cancer
cells using conventional drug delivery; however, accumulation of the drug inside of resistant
cells can be increased by inhibiting the function of the efflux pumps [16].
The objective of my research was to develop drug delivery methods to overcome the
resistance of multidrug-resistant cancer (MDR) cells. My hypothesis is that blocking the efflux
pumps while delivering cancer drugs directly to the cytosol of MDR cells will kill MDR cells as
effectively as sensitive cancer cells. My method for achieving this result used a targeted drug
delivery vehicle known as a folated eLiposome, which is a liposome containing an emulsion
droplet. I attempted two different controlled release mechanisms to vaporize the emulsion
droplet and release drugs directly to the cell cytosol: gold nanorod heating via laser, and
ultrasound.

3
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2.1

LITERATURE REVIEW

Liposomes as Drug Delivery Vehicles
Liposomes are one of the most common drug carriers. They were first discovered in 1961

[17] when A.D. Bangham and colleagues observed that phospholipids spontaneously formed
lipid bilayers when dispersed in water. Liposomes range in size from 0.02 to 10 μm and are
characterized as vesicles that have an aqueous core enveloped by a hydrophobic lipid bilayer
[18]. This allows for the possibility of transporting both hydrophilic drugs within the aqueous
core and/or hydrophobic drugs within the lipid bilayer (Fig. 1) [19].

Figure 1. Schematic representation of a drug loaded liposome (modified from [19]).

Encapsulating drugs inside of a carrier is commonly used to avoid systemic delivery of
chemotherapeutics and to reduce the negative side effects of chemotherapy. Additional
advantages of encapsulating drugs inside of liposomes include biocompatibility, prevention of
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premature degradation of encapsulated cargo, entrapment of both hydrophilic and hydrophobic
drugs, targeted delivery, site avoidance (entrapped drugs prevented from interacting with healthy
tissue) and regulation of biodistribution (locations where the liposomes travel inside the body) by
size or lipid component variation [19]. For example, in vivo studies by Gabizon et al. [20] show
that <2% of doxorubicin loaded inside of PEGylated liposomes (liposomes with polyethylene
glycol on the surface) is released during circulation, allowing for most of the loaded drug to be
released at the tissues where the liposomes accumulate. Encapsulation prevents the drugs from
interacting with any cells until they are released or escape from the drug carrier.
Liposomes can still interact with serum proteins and be cleared quickly from circulation
when opsonins bind to the liposome. When bound to liposomes, opsonins interact with receptors
on the surface of macrophages or hepatocytes, thereby enhancing uptake by these cells and
clearance from blood circulation [21]. In 1990, two different groups proposed to incorporate
polyethylene glycol (PEG) into the lipid bilayer in order to improve the circulation time of
liposomes [22, 23]. PEGylated liposomes, now often referred to as stealth liposomes, have
increased half-life, decreased plasma clearance, and decreased distribution volume compared to
non-PEGylated liposomes [24]. The PEG coating on liposomes reduces the adsorption of
opsonins on the vesicles and thus decreases the clearance of PEGylated liposomes by the
immune system [21, 24] and increases the probability that PEGylated liposomes will accumulate
at the tumor site.

2.1.1

Targeting of Liposomes
Passive targeting of drugs to cancer cells occurs when drug delivery vehicles are able to

collect at tumor sites without any external assistance. In some cases, liposomes passively target
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tumors because of their small size and via a mechanism known as the enhanced permeation and
retention (EPR) effect. Specifically, the EPR effect is that small particles, such as liposomes, can
escape from blood vessels into the tissue of tumors due to the leaky vasculature of the tumor [18].
Conversely, these same liposomes are too large to enter healthy tissues, which have less
permeable vasculature. However, within a single tumor the vascular permeability can vary, such
that particles as large as 200 nm can leak through at certain locations in the tumor while at other
locations particles as small as 4 nm may not be able to leak through [25]. Furthermore, once
extravasated the liposomes might flow right past the cancer cell without stopping to release its
drug. Therefore, while it is beneficial that the liposomes can passively target tumors, it would be
more effective if they were also able to actively target the cancer cells.
One way liposomes can actively target tumor cells is to attach a ligand to the outer
surface of the liposomes that has a corresponding receptor on the surface of the cancer cell.
Researchers are still looking for new molecular features that are uniquely specific to cancer cells,
such as an over expression of an uncommon receptor molecule on the cell surface. While one
specific receptor truly unique to cancer cells has yet to be discovered, researchers have found
receptors that are expressed at much higher levels in cancer cells than in normal cells. Ligands
commonly used to exploit this difference include folate, transferrin, and galactosamine [25]
because the corresponding receptors for these molecules are often overexpressed in rapidly
growing cells.
Folate is one of the oldest and most well-known ligands attached to liposomes, as many
cancer cells overexpress folate receptors [18]. The binding of the attached folate to the folate
receptor also induces endocytosis [26-28], which is the process of a cell invaginating a section of
its cell membrane to engulf a volume of external fluid. Thus, if folate is attached to the liposome,
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the cancer cells have a greater uptake of the liposomes into the cell compared to non-targeted
liposomes [9, 29], which may be only randomly and rarely endocytosed.
Targeted delivery allows more of the drug from PEGylated liposomes to accumulate on
the surface or within the cancer cells due to an increase in liposomes collecting at the tumor site
instead of circulating in the blood. However, without a quick release mechanism the drug is only
able to escape the liposome through diffusion across its lipid bilayer. Rapid release of the drug is
desirable over slow release so that the cells do not have time to respond by upregulating
expression of defensive proteins that block, inactivate, or pump out the drug. Quick release of the
drug from the liposome leads to increased efficacy.

2.1.2

Triggered Release

2.1.2.1 Passive Triggers
In order to provide faster and/or more controlled release, many different types of release
mechanisms have been studied, both through passive and remote triggers. Passive triggers rely
on the environment of the tumor to trigger the release of the payload at the tumor site. The most
common passive trigger is a response to a change in pH [30]. The extracellular pH of normal
tissues and blood is regulated at a constant pH of 7.4; the intracellular pH is about 7.2. The
extracellular pH of various solid tumors, however, can be as low as 5.7 due to rapid metabolism
and poor circulation [31]. Drug delivery vehicles that are endocytosed will also experience a
drop in pH, with a pH of 6.5 inside the early endosome, pH of 5.0-6.0 inside the late endosome,
and a pH of 4.0-5.0 inside the lysosome [32]. Therefore, drugs can be released inside or outside
of the cell depending on the pH sensitivity of the drug carrier. The drugs released inside of the
endosome/lysosome must still escape this compartment to the cytosol in order to have their
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desired effect. Drugs released outside of the tumor cells in response to the lower pH result in a
higher than average local extracellular concentration of the drug. However, the externally
released drug must still diffuse into the cell or be endocytosed by the tumor cells in order to have
a cytotoxic effect. Unfortunately, despite a higher extracellular concentration of the drug, cancers
that have developed multidrug resistance might still be able to pump out the drug before the drug
can induce a cytotoxic response.
Many pH-sensitive liposomes contain specially synthesized pH-sensitive lipids that are
incorporated into the liposomal bilayer [33]. These lipids will change in size or shape depending
on the acidity of the surrounding environment [34]. In an alternative approach, Nahire et al. have
developed a pH-sensitive liposome that does not require lipids that are structurally modified at a
reduced pH [35]. They encapsulate ammonium bicarbonate inside of their liposomes, which will
generate carbon dioxide gas bubbles and burst the liposome in response to hydronium ions
diffusing into the liposomes when in an acidic environment. The release of encapsulated cargo
from the burst liposomes by Nahire et al. is enhanced through the application of ultrasound, so
such release can be a combination of passive and active mechanisms.
Another common passive trigger is a response to a change in temperature. Thermosensitive liposomes [19, 36] are liposomes that incorporate a thermo-sensitive polymer which
undergoes a coil-to-globule transition when the polymer is heated above its lower critical
transition temperature. Therefore, thermo-sensitive liposomes are used in combination with mild
hyperthermia (sometimes found in large tumors or induced through external heating between 41
and 42°C) [19] in order to control the release of the liposomal payload. Methods for localized
hyperthermia in conjunction with thermo-sensitive liposomes are also being explored with the
various external triggers (magnetic [37], laser heating [38, 39], ultrasound [40]).
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2.1.2.2 Remote Triggers
Magnetic fields, light, electric fields, and ultrasound are externally applied stimuli
commonly used in triggered drug delivery. Each of these stimuli has advantages as well as
disadvantages. Magnetically responsive systems have the ability to guide the drug delivery
vehicle to a target location and have the possibility to perform diagnostics and therapy
simultaneously. One major disadvantage is the complexity involved in the setup of external
magnetic fields in order to achieve adequate focusing and penetration depth [41].
Light-triggered delivery systems are non-invasive and have the possibility of
spatiotemporal control. Another advantage of light-triggered release is the possibility of having a
one-time release or a repeatable on-off release. UV light has a disadvantage of low penetration
depth (~10 mm); however, near-infrared (NIR) light (650-900 nm) is able to penetrate deeper
because tissues do not absorb or scatter the light as much as the shorter wavelength light. A
current disadvantage of NIR-responsive systems is finding biocompatible photosensitive
materials that will be continue to be non-toxic after use (i.e. safe biodegradability and clearance
of nanoparticles) [41, 42].
Electroresponsive systems can have pulsed or sustained drug release using weak electric
fields (typically about 1 V). They offer significant freedom in the design of the device that
controls the electric signal, but they have low penetration depth and lack the ability to avoid
undesired tissue damage [41].
Ultrasound is an effective method to achieve spatiotemporal control, is noninvasive, lacks
ionizing radiations, and has the ability to control penetration depth by tuning frequency, duty
cycles and time of exposure. Ultrasound can also increase drug transport across cell membranes
and tissues. One potential drawback of ultrasound is the possibility of metastatic dissemination
9

[41], or the spread of cancer from its primary site to other distant organs in the body. The
following two sections will review the use of lasers and ultrasound to trigger the release of
therapeutics, as they are the two methods presented in this research to trigger the release of
doxorubicin from eLiposomes.

2.2

Lasers
Lasers can be designed to emit light at different wavelengths and intensities. One of the

challenges with light-activated biomedical applications is the ability of light to reach its target
location without being absorbed or scattered by other molecules in its path. Hemoglobin and
water have high absorption of visible and infrared light, respectively; however, they both have
minimal absorption of light between 650 and 900 nm, what has been termed the near-infrared
(NIR) window [43]. For this reason, NIR lasers have greater penetration depth in tissues than UV
lasers.
Light can be delivered from lasers continuously or in short (nano-femtoseconds) highenergy pulses. Continuous wave lasers are often used for laser-induced mild hyperthermia [44,
45]. Pulsed lasers are often used for imaging applications [46-48] and/or quick heating for
release of therapeutics [46, 49]. Pulsed lasers are not typically used for prolonged heating with
gold nanorods because the short, high-energy pulses can lead to particle structural changes and
ablation due to the excessive heating of the gold nanorods without sufficient cooling between
pulses [50].
Leung and Romanowski [51] review light-activated release from liposomes, which
includes the release by photochemical activation and photophysical activation. Content release
from liposomes through photochemical activation utilizes the destabilization of the lipid
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membrane by light induced (typically UV) isomerization, cleavage, or polymerization of its
components [51]. Photophysical activation does not involve any chemical changes in the
liposome bilayer or any components within the liposome. Rather, it involves thermal or
mechanical changes in the liposome or surrounding medium. The following section of the
literature review will focus on the heating of gold nanorods to induce a thermal change to trigger
release from liposomes.

2.2.1

Gold Nanorod Heating
Gold nanorods (GNRs) are often used for photothermal therapy because they can be

synthesized to absorb light over a wide range of optical frequencies, including the NIR window.
Gold nanorods are most effective at absorbing light and converting it to thermal energy when the
irradiating light wavelength corresponds to the oscillations of the electrons around the long axis
of the gold nanorods, a phenomenon known as localized surface plasmon resonance (LSPR)
[52]. Gold nanorod heating is commonly used for mild hyperthermia treatments (40-45°C) or
diagnostic imaging via vaporization of contrast agents [47, 53]. GNRs are also used for drug
delivery with temperature sensitive nanoparticles [54] and even DNA/siRNA delivery [55].
Gold nanorods are not used as frequently for drug release from liposomes, but there are
some investigators researching this and related types of light-activated release. Viitala et al. [56]
loaded GNRs inside of DPPC liposomes along with calcein (a model drug). They observed 60%
release of calcein after 15 min of illumination (3 W). Drug release from these liposomes was
attributed to heating the DPPC above its phase transition temperature (41°C) and thus increasing
the rate of diffusion of calcein out of the liposomes. Instead of encapsulating GNRs inside of
liposomes, Yu et al. [54] investigated the release of doxorubicin when Dox-loaded liposomes
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were co-delivered with a solution of GNRs. They found the greatest amount of release when
irradiating GNRs in the presence of Dox-loaded liposomes that also contained ammonium
bicarbonate (ABC-Lip). Han et al. [57] showed that CO2 bubbles were not generated at 37°C
(physiological temperature) using ABC-Lip; however, bubbles were generated at temperatures as
low as 42°C. Therefore, when GNRs were used to induce mild hyperthermia (approximately
45°C in the experiments by Yu et al.), CO2 bubbles could generate in ABC-Lip and facilitate
quicker release of Dox from the liposomes. Yu et al. [54] observed approximately 80% release of
Dox from ABC-Lip after 5 min of irradiation (810 nm, 1.6 W/cm2), whereas they observed only
30% Dox release from liposomes with ammonium sulfate instead of ammonium bicarbonate.
Gold nanorod heating can also be used to vaporize perfluorocarbon droplets [46, 47, 58,
59]. Liu et al. vaporized GNR-loaded perfluoropentane droplets and applied ultrasound to
facilitate the perforation of cell membranes using ultrasound and cavitation [58]. Zhong et al.
vaporized perfluorohexane to release paclitaxel from nanoparticles while concurrently using it as
a contrast agent for real-time imaging [46]. Using different loading procedures, Hannah et al.
[47] and Wilson et al. [59] loaded GNRs in perfluoropentane droplets to use as contrast agents
for imaging.

2.3

Ultrasound
Ultrasound (US) consists of pressure waves having frequencies of 20 kHz or greater [60].

The pressure waves from US are longitudinal compressional waves, in which the particles are
displaced in the same direction as the travelling pressure wave. If one were to “take a picture” of
the ultrasonic wave as it travels through a medium, one would see areas of rarefaction (regions of
low pressure) and areas of compression (regions of high pressure) [61]. As the ultrasonic wave
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propagates through the medium, it causes cyclic displacement of the particles without net
movement of the particles in any one direction. Ultrasonic waves can also be focused, reflected
and refracted through a medium [61, 62]. Under the right conditions it is possible to vaporize
liquid droplets [63, 64] and to cause acoustic cavitation [62, 65].
Important considerations for the phase change of liquid droplets (emulsions) and the
cavitation of the resulting gas bubbles include the peak negative pressure, frequency and
exposure time of the incoming ultrasound, as well as the size of the droplet or bubble [61].
Larger droplets are easier to vaporize in part because of the lower Laplace pressure of the droplet.
The Laplace pressure is the increase in pressure inside a suspended droplet (or bubble), and is
given by
2𝛾𝛾𝑔𝑔

(2-1)

∆𝑃𝑃𝐿𝐿𝐿𝐿 = 𝑅𝑅

𝑒𝑒𝑒𝑒

where ∆𝑃𝑃𝐿𝐿𝑝𝑝 is the Laplace pressure, 𝛾𝛾𝑔𝑔 is the interfacial energy of the droplet, and 𝑅𝑅𝑒𝑒𝑒𝑒 is the

radius of the droplet. The interfacial energy of the droplet is a function of the surfactant used to
stabilize the droplet. The Laplace equation shows that as the size of the droplet decreases, the
Laplace pressure increases, and the peak negative pressure needed to allow the droplet to
vaporize also increases in magnitude. These relationships are captured in the following equation
[66]
(2-2)

𝑃𝑃𝑈𝑈𝑈𝑈 ≤ 𝑃𝑃𝑣𝑣𝑣𝑣𝑣𝑣 (𝑇𝑇) − 𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎 − ∆𝑃𝑃𝐿𝐿𝐿𝐿 − 𝑃𝑃ℎ𝑦𝑦𝑦𝑦

where 𝑃𝑃𝑈𝑈𝑈𝑈 is the ultrasonic peak rarefactional pressure, 𝑃𝑃𝑣𝑣𝑣𝑣𝑣𝑣 (𝑇𝑇) is the vapor pressure of the liquid
of the droplet at temperature 𝑇𝑇, 𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎 is the atmospheric pressure, and 𝑃𝑃ℎ𝑦𝑦𝑦𝑦 is the hydrostatic
pressure (usually negligible compared to the other terms in Eq. 2-2).
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A nucleation event must occur to initiate the liquid-to-gas phase change of a droplet.
Mountford and Borden suggest that the stability of phospholipid stabilized PFC droplets is more
than simply stabilization through the Laplace pressure. Stability is also attributed with the high
energy barrier associated with homogeneous nucleation [67]. At a given peak pressure and pulse
length, lower frequencies of the incoming US increase the probability of a nucleation event
occurring within a droplet [63]. One explanation for this is that there is a longer time window in
which stochastic events may satisfy the inequality of Eq. 2-2 or exceed the activation energy
barrier for nucleation. The lower the US frequency and the more negative the rarefactional
pressure (higher amplitude in pressure wave), the more probable it is to vaporize droplets [63].
There are limitations to the peak negative pressure and frequency allowed for biological
applications. In 1991, Apfel and Holland observed that the ratio of the acoustic pressure and the
square root of the frequency can approximately predict the onset of collapse cavitation for a
single acoustic cycle [68]. This observation has led to the establishment of the Mechanical Index
(MI), which is a measure of the likelihood of collapse cavitation occurring (possibility to damage
healthy tissue), and is defined as
𝑀𝑀𝑀𝑀 =

𝑃𝑃 − /𝑀𝑀𝑀𝑀𝑀𝑀

(2-3)

�𝑓𝑓/𝑀𝑀𝑀𝑀𝑀𝑀

where 𝑃𝑃 − is the peak negative pressure amplitude and 𝑓𝑓 is the applied frequency. The onset of

collapse cavitation begins between MI values of 0.3-0.4 and detrimental biological effects begin
when MI > 1 [69]. This definition of MI assumes that there are stabilized gas pockets or free
bubbles present as nuclei for cavitation [62]. Modes for ultrasound delivery approved by the
Food and Drug Administration include frequencies between 0.02 – 7.5 MHz [70].
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2.4

Acoustic Droplet Vaporization
The use of sound waves to induce a phase change in a liquid emulsion droplet is known

as acoustic droplet vaporization (ADV). The liquids used in this work were perfluorocarbons
(PFCs); therefore, they will be the only liquids of interest in this literature review. PFCs are good
choices for biomedical application because of their low solubility in aqueous formulations and
very low toxicity [63]. Perfluoropentane (PFC5) and perfluorohexane (PFC6) have normal
boiling points of 29°C and 59°C respectively. However, when coated with a surfactant, both PFC
droplets (1 µm) can have a spontaneous phase transition temperature (to gas) above 70°C [65].
Mountford and Borden [67] report that the spontaneous vaporization of PFC droplets occurs at
temperatures around 90% of the critical temperature of the PFC (𝑇𝑇𝑐𝑐 =423.1K for PFC5 [71], 90%
𝑇𝑇𝑐𝑐 =107°C).

Ultrasound pressure waves change the local pressure inside and outside the PFC droplet,

thus providing a driving force for vaporization. The probability of nucleation within the PFC
droplet is proportional to the amount of time the droplet spends with its local pressure below its
vapor pressure (see Figure 2). Therefore, it can be proposed that acoustic droplet vaporization is
more likely as the frequency decreases, the number of cycles per pulse increases, the peak
negative pressure increases in magnitude, and the Laplace pressure decreases (lower interfacial
energy and/or increased droplet radius) [63].
Some recent research on ADV has centered on capturing the vaporization dynamics and
lifetime evaluation of PFC droplets using ultra-high speed optical imaging [72-81]. A recent
study by Shpak et al. [76] looked at the physical mechanism responsible for ADV and concluded
that it is initiated by the focusing of a nonlinear acoustic wave on a specific spot inside the
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droplet. The authors propose that the phenomenon of ADV is facilitated by the nonlinear
propagation of ultrasound, which builds up superharmonics necessary to induce a focusing effect
within the droplet. They observed that, depending on the diameter of the droplet and frequency
of the incoming ultrasound wave, the initial site of nucleation went from a random site in the
droplet, to one of two specific sites, and finally to one specific site. This site in the droplet is the
location where the focused pressure amplitude is maximal. This focusing effect (using the
droplet itself as a lens) could be obtained by either increasing the droplet diameter or by
increasing the frequency of the incoming ultrasound. Thus, higher frequency US can increase
ADV through a focusing of superharmonics, while lower frequency US (20 kHz) can increase
ADV through a greater time for stochastic events to occur.

Figure 2. Schematic of an ultrasonic acoustic wave in a PFC emulsion. The upper figure illustrates an US
acoustic wave whose peak rarefactional pressure stays above the vapor pressure of the PFC minus the
Laplace pressure. The lower figure illustrates a gas phase forming around the emulsion droplet when the
peak rarefaction pressure drops below the vapor pressure of the PFC minus the Laplace pressure. Figure
used by permission from [82].
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Miles et al. [83] investigated the nucleation pressure threshold in ADV and predicted that
the local pressure needed to nucleate a 10 µm PFC5 droplet at 25°C is -9.33 ± 0.30 MPa
(7.5MHz, 5 cycles/pulse). Their model combined classical homogeneous nucleation theory with
superharmonic focusing, and their model predictions agreed with approximately two-thirds of
their experimental data. This pressure threshold predicated by Miles et al. is for droplets much
larger than the ones used in experiments presented in this work (10 µm v. < 0.2 µm) and Miles et
al. also used a much higher frequency (7.5 MHz v 0.02 MHz). The size of the droplet is a factor
in deciding whether high or low frequency US would be better for inducing ADV. The focusing
effect for ADV is applicable for larger droplets, as used by Shpak et al. [76] and Miles et al. [83],
but not for small droplets as used in this work. Shpak et al. observed that a frequency of 5.0 MHz
was necessary for a focusing effect to induce ADV at one site for a 6-10 µm droplet [76],
whereas at 3.5 MHz there were two spots of nucleation. The size of the droplets proposed in this
research is on the order of 100-200 nm. The significantly smaller size of the droplet would
require frequencies outside of the FDA approved frequencies for US if focusing were the only
trigger. Therefore, lower frequencies of US were used in the research presented in this
dissertation and focusing is probably not involved in ADV. As noted above there is also a greater
probability for nucleation at lower frequencies due to a greater time window at a pressure below
the vapor pressure of the droplet.

2.5

Multidrug Resistance
Chemotherapy is a common treatment method for cancer and involves delivering cancer

drugs to a patient in an effort to kill the cancer cells without killing the patient. One obstacle of
successful chemotherapy is the development of multidrug resistance in which the cancer cells
develop resistance not only to the administered cancer drug but also to multiple unrelated drugs
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that can be structurally and/or functionally different [15]. Developing resistance to cancer drugs
will eventually require such a high dose of cancer drugs to kill the cells that is not manageable or
safe for the rest of the body. Multidrug resistance is manifest in patients whose tumor growth
initially responded to chemotherapy, but then shows a loss of response after the initial treatments
[84].
Several cellular factors have been attributed to causing multidrug resistance including a
decreased influx of drugs, an increased efflux of drugs (ATP dependent efflux pumps), activation
of DNA repair, activation of detoxifying systems (cytochrome P450), and blocked apoptosis (e.g.
decreased ceramide levels) [12]. While more than one resistance mechanism can be present in
any cancer cell population exposed to chemotherapeutics, one of the most studied and most
common mechanisms of multidrug resistance is an elevated expression of drug efflux pumps
[12-15]. The drug efflux pumps are energy dependent transmembrane proteins that are capable of
transporting a broad spectrum of unwanted compounds across the cell membrane [12]. Increased
numbers of drug efflux pumps lower the intracellular drug concentration quickly enough so that
the drug is unable to have a cytotoxic effect. Consequently, the sensitive cancer cells will die
after a chemotherapy treatment, while the multidrug-resistant (MDR) cancer cells will survive,
increasing the fraction of cells with MDR characteristics. Cancers that develop resistance in
response to treatment are said to have acquired resistance. Some cancers, however, have an
intrinsic overexpression of efflux pumps and are said to have primary or natural drug resistance
[85].
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2.5.1

Current Treatments to Overcome MDR
There have been multiple investigations to develop drugs that can inhibit, circumvent, or

overwhelm the efflux transporters of MDR cancer cells. The most common transporter studied is
the permeability glycoprotein (P-gp) [86]. Cancers with low initial levels of P-gp expression
show elevated levels of expression after commencement of chemotherapy. Furthermore, some
cancers that are intrinsically resistant to chemotherapy overexpress P-gp without any prior
exposure (i.e., renal, adrenocorticoid, hepatocellular, pancreatic, and colorectal carcinomas) [85].
Reversing multidrug resistance by inhibiting P-gp has been studied for more than two
decades [87]. There are currently three different generations of inhibitor compounds for the P-gp
pump with the classification based on their affinity for the transporters and the relative side
effects [15]. The first generation of P-gp inhibitors needed a high concentration of the inhibitor
that also resulted in an unacceptably high systemic toxicity. These included verapamil, quinine,
quinidine, cyclosporin A, nifedipine, tamoxifen and others, all of which were drugs that were
approved for other medical purposes but were found to inhibit P-gp as well [88]. However, the
clinical trials did show enough promise and encouraged the second generation of less toxic
inhibitors, most being analogues of first generation inhibitors [15].
Second generation inhibitors include Valspodar (cyclosporin D analogue), dexverapamil
(R-enantiomer of verapamil), dexnigulpidine (structural analog for nifedipine), cinchonine
(structural analog for quinidine) and toremifene (structural analog for tamoxifen). The second
generation inhibitors are more potent and selective, but clinical trials were generally
disappointing. These include the clinical trials that were halted due to elevated intrinsic toxicity
(dexverapamil) and poor efficacy (dexnigulpidine) [88].
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The third generation inhibitors are the most specific and only require nanomolar
concentrations. They are compounds designed with specific characteristics—such as lipophilicity,
positive charge at neutral pH, and/or the presence of aromatic rings—that are able to overcome
problems seen with the first and second generation compounds [88]. These inhibitors include
biricodar, laniquidar, zosuquidar, elacridar, and tariquidar [87]. As of 2016, these inhibitors still
show unwanted inherent toxicities and pharmacokinetic interactions in clinical trials, and none of
them have yet found general clinical use [89].
In short, despite decades of research and multiple clinical trials, no P-gp inhibitors are
currently in clinical use. The problems associated with poor performance of P-gp inhibitors
include poor specificity, low affinity for the binding site, interference with the physiological role
of P-gp, and interference with the pharmacokinetics of the associated chemotherapy [87]. One
major problem with systemic delivery of these inhibitors is that they will affect not only the
cancer cells, but normal cells as well, resulting in a large number of negative side effects.
Since shutting down P-gp pumps has yet to be proven “safe and effective” in killing
MDR cancer cells, another approach is to deliver the drug into the cell faster than it can be
pumped out. In this research, my goal was to very quickly load the cell cytosol with drug by
triggering the release of the drug from a liposomal carrier once the carrier was endocytosed by a
cancer cell. Slowing the removal of drug by inhibiting the P-gp pumps would help accomplish
this goal.

2.5.2

GNR Heating to Overcome MDR
No currently published articles were found that used GNRs to treat multidrug-resistant

cancer cells by releasing drug from a liposome or vaporizing an emulsion droplet. There are a
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few articles, though, that use laser heating via GNRs to facilitate the release or uptake of Dox
into MDR cells [90-93]. Zhang et al. [92] and Qiu et al. [90] developed different drug delivery
vehicles, but both trapped Dox inside of DNA and attached the complex directly to GNRs. The
Dox was released when the DNA denatured after GNR heating. Wang et al. [91] used the heating
of silica coated GNRs to increase the uptake of Dox in a Dox-resistant breast cancer cell line.
Zhong et al. [93] developed a Dox-loaded GNR-cored micelle to treat MDR cells. GNR heating
increased the local temperature of the micelles above the phase transition temperature of the
poly(ε-caprolactone) portion of the block copolymer making up the micelle. My research
attempted to use GNR heating to vaporize emulsion droplets located inside of a Dox-loaded
liposome in order to trigger cytosolic delivery. Results are presented in Chapter 6.

2.5.3

Ultrasound Used to Overcome MDR
Using ultrasound to induce a phase change in emulsions for drug delivery is a current

area of research [94-98], as are using microbubbles and US to deliver drugs to MDR cells [99104], using liposomes in an effort to overcome MDR [105-110], and using US to overcome
MDR [111-118]. However, there is currently only one published article (Deng et al. [119]) which
uses US, liposomes, and microbubbles to deliver drugs in an effort to overcome MDR. Deng et
al. [119] used a construct developed by Kheirolomoom et al. [120] of liposomes attached to a
PFC microbubble by an avidin-biotin linker (Figure 3). Doxorubicin was loaded into the
liposomes and their drug delivery vehicle was administered in vitro to a breast cancer cell line
resistant to doxorubicin (MCF7/ADR). The average size of their construct was about 2 µm,
which is too large to passively accumulate at tumor sites, and without any targeting moiety
attached to the construct there is no means of either actively or passively targeting cancer cells.
Nevertheless, the authors found that there was a reduction in viability of the MDR cells in vitro
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when US was applied in conjunction with their liposome-microbubble construct. Their construct
depends on the ability of the ultrasound and cavitation of the microbubble to cause pores in the
cell membrane of the cancer cells, making it easier for doxorubicin to enter the cell. Their study
hinted that rapid delivery to the cytosol could overcome or bypass MDR mechanisms. The
method presented in this dissertation is novel in that it will deliver the drug directly to the cytosol
of MDR cells using a different design than Deng et al. used but similar concepts of ultrasoundtriggered release. We hypothesize that rapid delivery directly to the cytosol of the cell will be
more effective at killing the MDR cancer cells.

Figure 3. Schematic illustration of the liposome–microbubble construct developed by Kheirolomoom et al.
Deng et al. loaded Dox in the liposomes and used US to trigger the release of Dox to MDR cells. Figure
used by permission from ref [120].

2.6

eLiposomes (folated)
Javadi et al. developed a method to encapsulate PFC nanoemulsions inside of liposomes

[66]. Briefly, lipids were dried onto the bottom of a round bottom flask and then rehydrated in
the desired buffer. As mentioned in Section 2.1, liposomes spontaneously form in aqueous
solutions with phospholipids. Ultrasound was used to reduce the size of the liposomes. The
liposomes were then extruded through a 200-nm filter to achieve a uniform distribution of
unilamellar liposomes. In a separate container, US was used to form emulsions of
22

perfluorocarbons which were extruded to 100 nm. The emulsions and liposomes were mixed
together in an equivolume ratio and sonicated on ice for 3 cycles of 30 s with 1 min pauses. The
lipid bilayer of the liposomes continually breaks and reforms around the emulsions, thus forming
eLiposomes (liposomes with emulsion droplets inside).
The eLiposomes were separated from the empty liposomes and free emulsions using a
pillow density separation technique. The eLiposome mixture was put in an Eppendorf tube, and
then NaCl, glucose, and sucrose (in that order) were carefully pipetted to the bottom of the tube.
After centrifugation (3000 rpm for 10 min) the eLiposomes collected between the
glucose/sucrose interface due to differences in density. Folate was attached by incubating
eLiposomes with PEG-folate micelles (synthesis described in [66]) for 1 hour (20 µL of micelles
for 1.5 mL of eLiposomes).
Lattin et al. investigated the release of calcein (a model drug) from eLiposomes [121, 122]
and found that increased exposure time, intensity of ultrasound, and droplet size all increased the
release of calcein from eLiposomes. Javadi et al. also showed that cytosolic delivery of calcein to
HeLa cells (not a MDR cell line) via folated eLiposomes can be controlled through the
application of ultrasound [9, 66]. The research presented in this dissertation attempted to use
ultrasound to control the cytosolic delivery of doxorubicin to multidrug-resistant cancer cells.

2.7

Loading of Drugs into Liposomes
Liposomes are versatile drug carriers in that they can entrap hydrophilic drugs in their

aqueous core and/or hydrophobic drugs in their bilayer. For liposomes made via the film
hydration technique, lipids are dried in a thin film on a flask and then rehydrated with another
solution. Drugs can be loaded during the synthesis of the liposomes (passive loading) by simply
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having the drug in the solution used to rehydrate the liposomes [123]. Javadi et al. [9] and Lattin
et al. [122] used passive loading to encapsulate calcein inside of eLiposomes. Passive loading of
drugs is an easy method to encapsulate drugs in liposomes; however, drugs loaded this way have
a relatively low encapsulation efficiency (<30%), resulting in a significant loss of unused drugs
[123]. Haran et al. developed a method to load amphipathic weak bases in liposomes using a pH
gradient [124]. Liposomes are formed by rehydration in an acidic buffer. Then the external fluid
is replaced by a solution with a neutral pH via a size-exclusion column. Drug in neutral solution
is then added to the neutral suspension of liposomes, and the neutral form (uncharged) of the
drug can diffuse into the liposome across its bilayer. Once inside, the acidic environment
protonates the drug and the charged drug can no longer cross the membrane. Often, the drug
precipitates and becomes trapped inside of the liposome. This is the most common method used
to encapsulate Doxorubicin inside of liposomes.

2.7.1

Doxorubicin
Anthracyclines are among the most effective cancer drugs developed. Doxorubicin (Dox)

(see Figure 4) was one of the first anthracyclines developed and is one of the anthracyclines
currently approved for clinical use [125]. There are currently three commercialized liposomal
drug formulations containing Dox (Doxil, Lipo-Dox, and Mycoet) [19]. Dox is used to treat
multiple types of cancer including breast cancer, Kaposi’s sarcoma, and ovarian cancer [125].
However, problems with its use include severe cardiotoxicity [125], multidrug resistance [126],
and typical side effects characteristic of all cancer drugs including hair loss, nausea, fatigue, etc.
Dox induces apoptosis through its intercalation of DNA in the nucleus of cells [127].
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Figure 4. Chemical structure of Doxorubicin. Figure used by permission from [128].

Doxorubicin is loaded into liposomes using remote loading via a transmembrane pH
gradient demonstrated by Haran et al. [124]. The method used in this dissertation is based on the
work from Lin et al. [98], which was modified from Haran et al. [124]. Briefly, the internal
compartment of the eLiposomes contains ammonium sulfate buffer with a pH of 4.5, while there
is a buffer containing free Dox (doxorubicin hydrochloride, Dox-NH3Cl) at a neutral pH (7.4)
external to the liposome. The Dox-NH3Cl is incubated with the eLiposomes. Although the DoxNH3+ cationic form cannot cross the liposomal bilayer, at neutral pH, the proton is removed and
the neutral doxorubicin (Dox-NH2) can diffuse across the liposomal bilayer. Once inside of the
liposome, the neutral doxorubicin (Dox-NH2) will become protonated, react with the sulfate,
precipitate [(Dox-NH3)2SO4], and become trapped inside of the liposome (Figure 5). Li et al.
[129] and Johnston et al. [130] show via cryo-microscopy that Dox will form fiber bundles as the
concentration of Dox inside of the liposome increases. The concentration of Dox can be
determined using a spectrophotometer and measuring the absorbance at 488 nm [98].
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Figure 5. Schematic representation of Dox encapsulation process in eLiposomes using a transmembrane
pH gradient.

2.8

Cancer Cell Lines

2.8.1

MCF-7 Cells
Michigan Cancer Foundation (MCF)-7 cells are a line of human breast cancer cells.

Doxorubicin is commonly used to treat MCF-7 cells [119, 131, 132]; however, MCF-7 cells can
develop MDR after exposure to doxorubicin [119]. Folate is also used to target MCF-7 cells via
folate-mediated endocytosis [133].

2.8.2

KB Cells

KB cells are a derivate of HeLa cells [134, 135] and have a high expression of folate
receptors [136], many times higher than MCF-7 cells. Doxorubicin is also used to treat KB cells
[137]. Dr. Gottesman and colleagues at the National Institute of Health (NIH) have developed a
MDR strain of KB cells (KB-V1) through culturing a sensitive KB strain (KB-3-1) in increasing
concentrations of vinblastine [138]. KB-3-1 cells were derived from KB epidermal carcinoma
cells (ATCC, Manassas, VA) after two subclonings [134]. Shen et al. showed that KB-V1 cells
are resistant to vinblastine, cochicine, and Dox [138].
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3

OBJECTIVES

The overall objective of this research was to develop a drug delivery method to overcome
the acquired resistance of multidrug-resistant cancer cells. As mentioned in Section 2.5, the
development or inherent nature of multidrug resistance in cancer cells is a significant obstacle in
treating cancer. This resistance often drives the required effective dosage of chemotherapy drugs
to a toxic level. The systemic administration of inhibitors to reverse multidrug resistance is still
problematic due to many unwanted side effects. The use of localized and controlled drug
delivery will significantly decrease unwanted side effects, and increase the effectiveness in
cancer treatment. The specific goals of this research were to:
I.

Investigate the effectiveness of triggered drug release in the cytosol of MDR cells
a. Confirm the stability of eLiposomes at temperatures above the normal boiling
point of perfluoropentane and investigate the mechanisms of calcein release from
eLiposomes at the higher temperatures
b. Determine the feasibility of controlled release of drugs from targeted eLiposomes
using gold nanorod heating via lasers
i. Synthesize gold nanorods and load them into targeted eLiposomes
ii. Use a low-powered continuous wave laser to vaporize emulsion droplets
iii. Deliver model drugs to the cytosol of MDR cells
c. Determine the cytotoxicity of drug-loaded targeted eLiposomes using
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i. Gold nanorod heating via lasers
ii. Ultrasound
II.

Investigate the enhanced killing of MDR cells by co-delivering an inhibitor with the
drug-loaded folated eLiposomes
It was our hypothesis that drugs delivered directly to the cytosol of MDR cells will be

able to kill the resistant cells as effectively as, or better than, the action of the free drug against
the non-resistant cells. The delivery of cancer drugs directly to the cytosol of cells via
vaporization of emulsion droplets inside of targeted liposomes provides a novel way to treat
multidrug-resistant cancer cells. We reasoned that localizing the drug to the cytosol would
minimize the unwanted side effects as well as decrease the effective systemic dose of current
cancer treatments. This delivery method may then provide the ideal location for any therapeutic
that needs to be delivered to the cytosol or that can be easily transported from the cytosol to the
nucleus.
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4

4.1
4.1.1

MATERIAL AND METHODS

Materials and Equipment
Materials
The phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-

dipalmitoyl-sn-glycero-3-phosphate, sodium salt (DPPA) were purchased from Echelon
Biosciences, Inc (Salt Lake City, UT). 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[amino(polyethylene glycol)-2000], ammonium salt (DSPE-PEG-NH2) was obtained from
Laysan Bio, Inc. (Arab, AL). Dodecafluoro-n-pentane (PFC5) was purchased from SynQuest
Laboratories (Alachua, FL). Calcein was obtained from MP Biomedicals, LLC (Solon, OH).
Phosphate buffered saline, 10x solution (PBS), sodium chloride (NaCl), sodium hydroxide
(NaOH), tetrahydrofuran (THF), pyridine, ammonium sulfate ((NH4)2SO4), sodium lauryl sulfate
(SDS), and Whatman® Nuclepore Track-Etch Membrane filters (19 mm diameter) were
purchased from Fisher Scientific (Hampton, NH). Sodium borohydride, powder 98+% (NaBH4)
was purchased from Acros Organics (New Jersey, USA). Dulbecco’s modified eagle medium
(1X) (DMEM)(+ 4.5 g/L D-glucose, + L-glutamine, - sodium pyruvate), RPMI 1640 (1X) (+ Lglutamine, + phenol red, - folic acid), penicillin streptomycin (Pen Strep), and fetal bovine serum
(FBS) were purchased from Gibco® by Life Technologies (Grand Island, NY). 1,1'-dioctadecyl3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI) and 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) were purchased from Molecular Probes™ by Life
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Technologies (Eugene, OR). Trypsin-EDTA was purchased from Invitrogen (Carlsbad, CA).
Sucrose, chloroform, sulfuric acid (H2SO4), L-ascorbic acid, and silver nitrate (AgNO3) were
purchased from Avantor Performance Materials, Inc (Phillipsburg, NJ). Glycerol was purchased
from MilliporeSigma (Billerica, MA). Nitrogen gas was purchased from Airgas (Salt Lake City,
UT). Doxorubicin HCl injection, USP (10mg/mL) was purchased from Pfizer (New York, NY).
Vinblastine sulfate injection (1 mg/mL) was purchased from APP Pharmaceuticals, LLC
(Schaumburg, IL). Cholesterol (powder, BioReagent, suitable for cell culture, ≥99.0%), α-Dglucose, gold(III) chloride trihydrate (HAuCl4), hexadecyltrimethylammonium bromide (CTAB)
(BioUltra, for molecular biology, ≥99.0%), 1H,1H,2H,2H-perfluorodecanethiol (PFD-SH), folic
acid (≥ 97%), ninhydrin, (±)-verapamil hydrochloride (≥99% (titration), powder), dimethyl
sulfoxide, ≥99.9% (DMSO), methanol, N,Nˊ-dicyclohexylcarbodiimide, 99% (DCC),
dichloromethane (CH2Cl2), L-glutamic acid potassium salt monohydrate (≥99%, (HPLC),
powder), and poly(ethylene glycol) methyl ether thiol (Average Mn, 2000) (mPEG-SH) were
purchased from Sigma-Aldrich (St. Louis, MO). Hydrochloric acid SVS was purchased from
Spectrum Chemical Mfg. Corp. (New Brunswick, NJ). Dimethyl sulfoxide-D6 (D, 99.9%) +0.05%
V/V TMS DLM-10TB-10 was purchased from Cambridge Isotope Laboratories, Inc. (Andover,
MA). Poly-L-lysine (MW 30-70kD) 12 mm round, No. 1 German glass coverslips were
purchased from Corning Inc. – Life Sciences (Oneonta, NY). Sephadex G-25 columns were
purchased from GE Healthcare Life Sciences (Pittsburgh, PA). KB-3-1 and KB-V1 cells were
kind gifts from Dr. Michael Gottesman (NIH, Bethesda, MA). Greiner Bio-One CELLSTAR®
24-well cell culture plates were purchased from BioExpress (Kaysville, UT). Cell culture flasks
were purchased from Sarstedt AG & Co (Nümbrecht, Germany). Borosilicate micro glass cells
(1 mm I.D., 50 mm long) were purchased from Friedrich and Dimmock, Inc. (Millville, NJ). All
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water used was deionized water distilled through a Corning Mega-Pure™ MP-1 Glass Still
(ddH2O).

4.2

Methods
The experiments done in this work require the creation of emulsions, liposomes,

eLiposomes and gold nanorods. I will first explain the methods to create eLiposomes loaded with
the fluorescent dye calcein (Section 4.2.1) and the experiments to measure the release of calcein.
The calcein-loaded eLiposomes were used observe the stability of eLiposomes at body
temperature (37°C) over time and the results are presented in Chapter 5. I will then explain the
methods used to synthesize gold nanorods and to transfer them to perfluoropentane (Section
4.2.2). The results of the gold nanorod experiments are presented in Chapter 6. In Section 4.2.3, I
will explain the methods used to created doxorubicin-loaded folated eLiposomes (folated
eLipoDox) and the experiments used to observe cellular uptake and cytotoxicity of folated
eLipoDox. The results of these experiments are presented in Chapter 7. Finally, I will describe
the methods used to measure the enhanced cytotoxicity of co-delivering folated eLipoDox with
verapamil. The results of the co-delivery experiments are presented in Chapter 8.

4.2.1

Calcein Release Experiments (Ch. 5)

4.2.1.1 PFC5 Emulsion Droplet Formation
Calcein loaded eLiposomes were synthesized as described in [139]. Briefly, DPPA in
chloroform was dried on a flask under vacuum using a rotary evaporation and was subsequently
rehydrated in PBS (5 mg/mL). Once the flask was cooled in an ice-water bath, PFC5 (0.1g/mg
DPPA) was added to the flask. The solution was then sonicated on ice with a 20 kHz probe
(Sonics and Materials, CVX400, Newton, CT) at 1 W/cm2 for 1 min. The DPPA coated PFC5
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emulsion droplets were filtered (LiposoFast™, Avestin, Ottowa, ON, Canada) through a 100-nm
filter.

4.2.1.2 Liposome Formation
Liposomes were synthesized by drying DPPC, cholesterol, and DSPE-PEG(2000) amine
onto a glass round bottom flask in a 3:1:1 molar ratio. The lipids were then rehydrated in PBS
(50 mg/mL) and filtered through a 200-nm filter to make a uniform distribution of unilamellar
liposomes.

4.2.1.3 Calcein eLiposomes
Calcein-loaded eLiposomes were made by mixing 2 mL of 30 mM calcein with 1 mL of
100-nm DPPA-coated PFC5 emulsion droplets and 1 mL of 200-nm liposomes. This solution
was sonicated on ice for three 30-s intervals with 60-s pauses between each sonication. External
calcein was removed by centrifugation (2500 rpm, Eppendorf 5414C, Hamburg, Germany). The
supernatant was discarded and the eLiposome pellet was resuspended in 1.5 mL of PBS. This
washing procedure was repeated twice more to remove nearly all of the external calcein.
Calcein-loaded eLiposomes were separated from external emulsion droplets and empty
liposomes using a pillow density separation technique. 0.3 mL eLiposome mixture was pipetted
into a 1.5 mL centrifuge tube. NaCl, glucose, and sucrose (~0.3 mL each) were then slowly
added to the bottom of the centrifuge tube using a Pasteur pipet in order of increasing density,
and centrifuged for at 3000 rpm for 10 min. Calcein-loaded eLiposomes accumulate between the
sucrose and glucose layers, whereas empty liposomes remain between the NaCl and glucose
layers. The external emulsion droplets amass at the bottom (below the sucrose layer).

32

4.2.1.4 Calcein Release from eLiposomes
Calcein concentration inside of the eLiposomes was estimated to be 15 mM, which is in
the self-quenched region and thus has minimal fluorescence. The fluorescence of calcein
increases as calcein is released from eLiposomes, and the concentration of calcein is proportional
to fluorescence. For these experiments 30 µL of calcein-loaded eLiposomes were mixed with 2
mL of PBS and placed in a cuvette in a QuantaMaster fluorometer (Photon Technology
International, Birmingham, NJ, USA). Temperature was kept constant and the fluorescence was
continuously recorded with the excitation and emission wavelengths set at 488 and 520 nm,
respectively.

4.2.2

Gold Nanorod Experiments (Ch. 6)

4.2.2.1 GNR Synthesis
Gold nanorods were synthesized using a slightly modified procedure to the synthesis
presented by Nikoobakht et al. [140]. Briefly 0.28 mL of AgNO3 (0.004 M) was added to 5 mL
of aqueous CTAB (0.2 M) and placed in a 28°C water bath (growth solution). In another vial, 5.0
mL of HAuCl4 (0.5 mM) was added to 5 mL of CTAB (0.2 M) (seed solution). 600 µL of ice
cold NaBH4 (0.01 M) was added to the seed solution and stirred for 2 min. The seed solution was
then placed in the water bath and 5 mL of HAuCl4 (1 mM) was added to the growth solution and
stirred for 2 min. 70 μL of ascorbic acid (0.0788 M) was then added to the growth solution.
13.35 μL of the seed solution was then added to the growth solution and stirred for 2 min before
being placed in the water bath. The growth solution remained in the water bath overnight before
taking an absorption spectrum (Beckman Coulter DU-640 UV, Fullerton, CA).
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4.2.2.2 GNR Phase Transfer
Once the GNRs were synthesized, we needed to transfer them to PFC5. Gold nanorods
were transferred from an aqueous phase to PFC5 using a modified procedure of Wilson et al.
[59]. Briefly, 5 mL mPEG-SH (2.0 mg/mL) was added to 5 mL of the GNR growth solution.
This solution was sonicated (1.25 W/cm2, 20 kHz, Sonics and Materials, CVX400, Newton, CT)
for 2 min at room temperature (~23°C). The solution was left at room temperature for 2 hours in
the dark before being centrifuged at 11,000 rpm for 10 min (Eppendorf 5414C, Hamburg,
Germany). The GNRs were resuspended in 5 mL of ddH2O and the solution was again sonicated
for 2 min and allowed to sit for 1 hour at room temperature in the dark. The GNR solution was
then centrifuged again (11,000 rpm, 10 min) and resuspended in 5 mL of THF. The previous
sonication and washing steps were designed to replace the CTAB on the surface of the GNRs
with mPEG-SH. Five mL of PFD-SH in THF (3 µL/5 mL) was added to the GNR solution. This
solution was then sonicated in an ultrasonic bath (120V, 50/60Hz, Sonicor Instrument
Corporation, Copiague, NY) for 30 min at room temperature, and 60 min at 50°C. The vials were
then left overnight in the dark. This part of the procedure was done to replace some of the
mPEG-SH or remaining CTAB with the PFD-SH. The GNR solution was then centrifuged for 10
min at 11,000 rpm, and the GNRs were resuspended in 5 mL of CH2Cl2. One mL of the GNRs
was then placed in a separate vial and the CH2Cl2 was evaporated with a flowing stream of
nitrogen gas. A pink residue was left on the bottom edges of the vial. Then 0.25 mL of PFC5 was
added to the vial, and the solution was sonicated in the ultrabath sonicator for 3 min at room
temperature. Two mL of DPPC in ddH2O (0.2 mg/mL) was then added to the GNR-PFC5
solution and the solution was probe sonicated for 20 s at 1 W/cm2 at room temperature.
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4.2.2.3 PFC5 Vaporization Using GNR Heating
The PFC5-GNR emulsion droplet solution was placed inside of a borosilicate micro glass
cell and irradiated with either a 450 mW continuous wave (cw) laser (785 nm, BWF1 series,
B&W TEK Inc., Newark, DE) in a chamber at 37°C, or a pulsed laser (mode-locked ti:sapphire
laser capable of producing pulses of about 30 femtoseconds, Dr. John Colton’s lab, BYU) at
room temperature. No observable vapor bubbles were observed after laser irradiation.

4.2.3

Folated eLipoDox Experiments (Ch. 7)

4.2.3.1 DSPE-PEG-Folate Synthesis
Folate was conjugated to DSPE-PEG-NH2 using a previously described method [141]
with slight modifications. Briefly, 16.7 mg of folic acid was dissolved in 0.667 mL of anhydrous
DMSO. DSPE-PEG-NH2 (66.7 mg) was dissolved in 0.333 mL of pyridine and added to the folic
acid solution. N,Nˊ-dicyclohexylcarbodiimide (DCC) (21.7 mg) was then added to the reaction
mixture. Nitrogen gas was added to the round bottom flask and the round bottom flask was
capped. The reaction proceeded under mild stirring for 4 hours at room temperature (~23°C) in
the dark. Every hour the reaction progress was checked using thin layer chromatography on
silica gel plates using a 75:36:6 chloroform/methanol/water mobile phase. Ninhidryin spray (0.2
g ninhydrin/100 mL ethanol) was used to confirm the disappearance of the amine on the DSPEPEG-NH2. The pyridine was then removed by rotary evaporation and 6 mL of ddH2O was added
to the mixture. The solution was centrifuged to remove trace insolubles and the supernatant was
dialyzed in 3500 molecular weight Spectra/Por® (Spectrum Laboratories, Inc., Rancho
Dominguez, CA) tubing against NaCl (50 mM, 2 x 700 mL) and then ddH2O (3 x 700 mL). An
equal amount of chloroform was added to the dialysate to extract the product (DSPE-PEGfolate). Hydrochloric acid was added to the aqueous phase to make the product more soluble in
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chloroform, as was seen by the shift of the characteristic yellow of folate from the aqueous to
chloroform phase. This chloroform phase was collected and stored at 4°C. H-NMR was used to
confirm the synthesis of DSPE-PEG-folate (in DMSO-d6).

4.2.3.2 PFC5 Emulsion Droplet Formation
eLiposomes were synthesized using a modified procedure of Javadi et al. [66] in order to
make larger sized eLiposomes. Briefly, DPPA in chloroform was dried on a flask using rotary
evaporation and was subsequently rehydrated (5 mg/mL) in 129 mM ammonium sulfate (pH
4.5). Once cooled, PFC5 (0.02g/mg DPPA) was added to the DPPA solution. The mixture was
then sonicated on ice with a 20 kHz probe (Sonics and Materials, CVX400, Newton, CT) at 1.25
W/cm2 (30% amplitude setting) for five 1-min intervals with a 1-min pause between each
sonication. The DPPA coated PFC5 emulsion droplets were extruded (LiposoFast™, Avestin,
Ottowa, ON, Canada) through a 100-nm polycarbonate track-etched filter (Whatman®
Nuclepore).

4.2.3.3 Liposome Formation
Liposomes were synthesized by drying 37.5 mg DPPC and 12.5 mg cholesterol onto a
glass round bottom flask. For folated liposomes, 0.2 mL of the DSPE-PEG-folate in chloroform
(see section 4.2.3.1) was added to the lipids before drying. The lipids were then rehydrated (50
mg/mL) in 129 mM ammonium sulfate (pH 4.5) and extruded through a 400-nm polycarbonate
filter to make a uniform distribution of unilamellar liposomes.
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4.2.3.4 eLiposome Synthesis
eLiposomes were made by mixing 1 mL of DPPA-coated PFC5 emulsion droplets and 1
mL of liposomes. This solution was sonicated (1 W/cm2) on ice for three 15-s intervals with 60-s
pauses between each sonication. eLiposomes are separated from external emulsion droplets and
empty liposomes using a pillow density separation technique as described in section 4.2.1.3.
Briefly, eLiposomes followed by NaCl and then sucrose (~0.4 mL each) were added to a
centrifuge tube and centrifuged at 3000 rpm for 10 min. The eLiposomes were collected and
passed through a Sephadex G25 column to replace the external media with PBS (pH 7.4),
establishing a transmembrane pH gradient.

4.2.3.5 Doxorubicin Loading
Doxorubicin was loaded into eLiposomes using a transmembrane pH gradient. An equal
volume of Dox in PBS (0.1 mg/mL) was added to the eLiposomes and left for 18 hrs in the
fridge (4°C). The solution was then pipetted and centrifuged for 10 min at 3000 rpm. The Dox
loaded eLiposomes (eLipoDox) were resuspended in PBS and diluted to an absorbance value of
0.5 (Beckman Coulter DU-640 UV, Fullerton, CA) measured at 480 nm. This corresponds to a
Dox concentration of 0.024 mg/mL.

4.2.3.6 Dynamic Light Scattering and Zeta Potential
Folated eLipoDox and non-targeted eLipoDox were sized using dynamic light scattering
(NanoBrook Omni, Brookhaven Instruments Corporation, Holtsville, NY). The zeta potential of
folated Liposomes and non-targeted liposomes were measured using phase analysis light
scattering (NanoBrook Omni, Brookhaven Instruments Corporation, Holtsville, NY).
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4.2.3.7 Doxorubicin Release Experiments
Experiments investigating the release of doxorubicin from eLiposomes using ultrasound
(Sonics and Materials, CVX400, Newton, CT) were conducted using a QuantaMaster
fluorometer (Photon Technology International, Birmingham, NJ, USA). Folated eLipoDox or
non-targeted eLipoDox (20 µL) was added to PBS (2 mL) in a cuvette and gently mixed by repipetting. Fluorescence was measured using excitation and emission wavelengths of 475 nm and
588 nm, respectively. After 50 s, the reading was stopped, the cuvette was removed, and
ultrasound was applied (1 W/cm2, 20 kHz, 2 s total of US applied in 20 sec of 0.1-s pulses, 1:10
duty cycle). The cuvette was then replaced and the reading continued. This procedure was
repeated one more time. SDS (30 µL) was then added to the solution and gently re-pipetted to
release all of the Dox, and the fluorescence was then measured.

4.2.3.8 Cell Culture
KB-3-1 and KB-V1 cells were cultured in DMEM containing 10% FBS and 1% Strep
Pen and incubated at 37°C, 5% CO2. Vinblastine (3.5 µg/5 mL DMEM) was added to the KB-V1
cells growth media to maintain its multidrug resistance. Before experiments, cells were washed
and grown for 48 hours in folate free RPMI media (10% FBS, 1% Step Pen), and no vinblastine
was added to KB-V1 cells. Cells were seeded in a 24-well plate 24 hours before the addition of
drugs at an approximate cell density of 1 x 104 and 2 x 104 for KB-3-1 and KB-V1 cells,
respectively.

4.2.3.9 Confocal Experiments
KB-V1 cells were seeded at approximately 6 x 104 cells on poly-L-lysine (MW 30-70kD)
12 mm round, No. 1 German glass coverslips in a 24-well plate. Cells had been growing for 48
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hours in RPMI folate free media before the addition of folated or non-targeted eLipDox (0.2 mL,
0.5 Abs at 480 nm). Drugs were allowed to incubate (37°C, 5% CO2) for 2 hours before the
media was removed. Cells were then rinsed with 0.5 mL of ice-cold PBS. The PBS was removed
and 1.0 mL of ice-cold methanol was added to the cells and the 24-well plate was kept on ice for
10 minutes. The methanol was removed and the cells were rinsed twice with ice-cold PBS. The
cell-covered cover slips were then placed on plain selected precleaned VWR micro slides (25 x
75 mm, 1.0 mm thick, VWR International, LLC, Radnor, PA) using 5 µL of a 50%
glycerol/ddH2O solution. Confocal images were obtained using an Olympus FluoView FV1000
(Tokyo, Japan) confocal microscope.

4.2.3.10 MTT Assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was used to
measure the metabolic activity of living cells [142]. It has a yellow color; however metabolic
enzymes in living cells can reduce MTT to an insoluble formazan, which is purple. For cell
experiments, 0.1 mL of MTT in PBS (5 mg/mL) was added to the cells (0.9 mL growth media)
and incubated at 37°C, 5% CO2 for 2 hours. The growth media containing MTT was removed
and the formazan was solubilized using 1.0 mL of DMSO. After 15 min, the absorbance at 570
nm and 700 nm was measured using a Synergy™ MX multimode microplate reader (BioTek®
Instruments, Inc., Winooski, VT). Seeding density for cells was optimized to obtain an
absorbance value (570 nm) of approximately 1.0 for the PBS control.

4.2.3.11 IC50 Experiments
Doxorubicin (0.2 mL) was added to the cells (1.0 mL growth media) in a 24-well plate to
obtain Dox concentrations between 0.001 and 500 µM. PBS was used as a positive control. The
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media was removed after 2 hours incubation (37°C, 5% CO2) and the cells were rinsed with 0.5
mL of PBS. The PBS was then replaced with fresh DMEM (10% FBS, 1% Pen Strep). An MTT
assay was performed 48 hours later.

4.2.3.12 Ultrasound Experiments with Folated eLipoDox
KB-3-1 and KB-V1 cells were seeded in a 24-well plate, and 0.2 mL of PBS, Dox,
eLipoDox, or folated eLipoDox was added to cells (1.0 mL of RPMI). Dox, eLipoDox, and
folated eLipoDox had an absorbance of 0.5 measured at 480 nm (Beckman Coulter DU-640 UV,
Fullerton, CA), which corresponds to a final Dox concentration of 7 µM. Cells were incubated
(37°C, 5% CO2) for 2 hours with the drugs. To minimize the cellular damage or detachment of
the cells from the bottom of the well during insonation, 1.8 mL of DMEM was added to the cells
just before ultrasound was applied to some of the cells (1 W/cm2, 20 kHz, 2 s total of US applied
in 20 sec of 0.1-s pulses, 1:10 duty cycle). The probe was placed in the growth media so that the
tip was just below the liquid surface. Following ultrasound, the media was removed and the cells
were rinsed with 0.5 mL PBS to remove any drug not internalized by the cells. After removing
the PBS, 0.9 mL of fresh DMEM (10% FBS, 1% Pen Strep) was added to the cells. An MTT
assay was performed 48 hours after US.

4.2.3.13 Dox Loading with Glutamate vs Sulfate
Folated liposomes were synthesized as described in section 4.2.3.3 using either
ammonium sulfate or potassium glutamate to rehydrate the liposomes and emulsion droplets
(4.2.3.2). Otherwise, eLiposome synthesis proceeded as described in section 4.2.3.4.
Doxorubicin was loaded into folated eLiposomes using a pH gradient as described in 4.2.3.5,
except that the Dox solution added to folated eLiposomes had a concentration of 2 mg/mL,
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instead of 0.1 mg/mL. The loading process was at 4°C for 17 hours, and then the folated
eLipoDox solutions sat at room temperature (23°C) for 90 min.

4.2.4

Co-delivery of Folated eLipoDox and Verapamil Experiments (Ch. 8)
Folated and non-targeted eLipoDox were synthesized as described in section 4.2.3. Cell

culture (4.2.3.8) and MTT assays (4.2.3.10) were also performed as described in section 4.2.3.

4.2.4.1 Optimal Verapamil Concentration
For determining the cytotoxicity of verapamil, KB-V1 and KB-3-1 cells were seeded in
24-well plates. After 24 hours, 0.1 mL of verapamil (0.003–3 mg/mL) was added to the cells (in
1.0 mL growth media) followed by 0.2 mL of PBS. The PBS was added as a substitute for the
0.2 mL of Dox that was added in the co-delivery experiments with Dox and verapamil. For the
co-delivery experiments with Dox and verapamil, 0.2 mL of 50 µM Dox was added following
the addition of verpamil. The drugs were allowed to incubate (37°C, 5% CO2) for 2 hours before
the media was removed. The cells were then washed with 0.5 mL of PBS. The PBS was removed
and 0.9 mL of fresh DMEM (10% FBS, 1% Pen Strep) was added. The cells were incubated for
48 hours, and then the MTT assay was performed.

4.2.4.2 Co-delivery of Folated eLipoDox and Verapamil
Folated eLipoDox was synthesized and doxorubicin and folated eLipoDox were diluted
to absorbance (480 nm) values of 0.5 (Beckman Coulter DU-640 UV, Fullerton, CA). A solution
of verapamil in PBS (3 mg/mL) was also prepared. KB-V1 and KB-3-1 cells were cultured in
folate free RPMI (10% FBS, 1% Pen Strep) and seeded in a 24-well plate. Verapamil solution or
PBS (0.1 mL of either) was added to the cells (in 1.0 mL RPMI) followed by the addition of 0.2
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mL of PBS, Dox or folated eLipoDox. The cells were incubated (37°C, 5% CO2) with the drugs
for 2 hours. Then 1.8 mL of DMEM was added to the cells just before ultrasound was applied to
some of the cells (1 W/cm2, 20 kHz, 2 s total of US applied in 20 sec of 0.1-s pulses, 1:10 duty
cycle). The probe was placed in the growth media so that the tip was just below the surface.
Following insonation, the media was removed and the cells were rinsed with 0.5 mL PBS to
remove any drug not internalized by the cells. After removing the PBS, 0.9 mL of fresh DMEM
(10% FBS, 1% Pen Strep) was added to the cells. An MTT assay was performed 48 hours after
insonation and washing.
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5

5.1

RELEASE MECHANISM OF CALCEIN AT HIGHER TEMPERATURES

Introduction
Previous studies [9, 66] showed that eLiposomes were capable of delivering a model drug

(calcein) to cells via ultrasound; however, the question remained as to the stability of the
eLiposomes at temperatures above the normal boiling point of perfluoropentane (PFC5) (29°C).
eLiposomes need to be stable at body temperature (37°C) in order to reach the target tumor
without premature release of the therapeutic. Premature release can happen from the therapeutic
diffusing through the liposomal bilayer or from vaporization of the PFC5 emulsion before
ultrasound (US) is applied. Because the PFC5 emulsion droplet increases 125-fold in volume as
it changes from a liquid to a vapor phase, and the bilayer can only sustain 3% expansion by area
and maintain integrity[143, 144], vaporization of only a fraction of the emulsion droplet would
be enough to rupture the liposomal bilayer and release the drug.
Perfluorocarbon (PFC) emulsion droplets have been shown to be stable at physiological
temperatures [65, 145-148], although the temperature is above its normal boiling point. Many
studies have attributed this phenomenon to the added Laplace pressure on the droplet, which will
increase the temperature at which vaporization occurs and make the droplet stable at
physiological temperatures. A recent study by Mountford and Borden [67], however, suggests
that the added Laplace pressure on nanodroplets is not sufficient to explain the high temperatures
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needed to vaporize PFC emulsion droplets. They contribute the stability of PFC droplets to the
high energy barrier associated with homogeneous nucleation.
Experiments with Dr. Ghaleb Husseini were conducted to determine the thermal stability
of eLiposomes by measuring the kinetics of calcein release at various temperatures. Calcein was
loaded in eLiposomes at a concentration of 15 mM, which quenches calcein fluorescence.
Calcein release at temperatures above (37°C, 49°C, 59°C) and below (25°C) the natural boiling
point of PFC5 was measured using a QuantaMaster fluorometer (Photon Technology
International, Birmingham, NJ, USA). No ultrasound was applied in these experiments. The
purpose of these experiments was to investigate the thermal stability of eLiposomes at
temperatures above the normal boiling point of PFC5. Results from these experiments were
published in the Journal of Colloid Sciences and Biotechnology [139] and are presented below.

5.2

Results
Figure 6 shows the results of the experiments done to determine the stability of

eLiposomes as a function of temperature. The release of calcein from the eLiposomes is depicted
as a function of time for four different temperatures – 59, 49, 37, and 25°C. A rapid release of
calcein from eLiposomes was observed at 59°C and 49°C (89% and 57 % after 1 hour,
respectively), but minimal release was observed at body temperature (37°C) or room temperature
(25°C) (8% and 5% after 1 hour, respectively). The latter temperature is below the normal
boiling point of PFC5 (29°C), but the former temperatures are significantly above the normal
boiling point. The stability of the PFC5 emulsions above its normal boiling point, specifically at
37°C, was previously attributed to the Laplace pressure, which increases the internal pressure
inside the droplet such that the vapor pressure remains below the local (internal) pressure and no
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gas forms [149]. However, Mountford and Borden suggest that their data are more consistent
with the high energy barrier associated with homogeneous nucleation [67]. We postulate and
discuss three possible causes for the rapid release observed at 49°C and 59°C, namely: 1)
increasing temperature increases the passive diffusion of calcein across the liposomal bilayer 2)
the phospholipids in the bilayer experience a membrane transition at its transition temperature 3)
the liposome is ruptured by the formation of a gas bubble. Below, we test these postulates against
the experimental evidence to reject or accept possible physical mechanisms at play in this drug
delivery system.
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Figure 6. Average fraction of calcein release from eLiposomes incubated at various
temperatures. Error bars indicate the standard deviation of several experiments (n ≥ 3) at
selected times.

5.3
5.3.1

Discussion
Temperature Dependent Diffusivity
For the first postulate, we assume that the temperature dependence of the diffusivity of

calcein through the lipid bilayer membrane can be modeled by an Arrhenius-type equation,
−𝐸𝐸

(5-1)

𝐷𝐷 = 𝐷𝐷𝑜𝑜 exp � 𝑅𝑅𝑅𝑅𝑑𝑑 �
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where 𝐷𝐷 is the diffusivity coefficient, 𝐷𝐷𝑜𝑜 is the pre-exponential constant, 𝐸𝐸𝑑𝑑 is the activation

energy for diffusion, 𝑅𝑅 is the universal gas constant, and 𝑇𝑇 is the absolute temperature. Initial
release rates, which are proportional to 𝐷𝐷/𝐷𝐷𝑜𝑜 , were calculated and the negative of the natural

logarithms of the release rates were plotted versus the inverse of absolute temperature. The data
were then fit using a linear equation (see Figure 7). Using the slope of the fitted line, the
activation energy for diffusion was estimated to be 110 kJ/mol.
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Figure 7. Negative of the natural logarithms of the initial fractional calcein release rate
versus inverse temperature. The line is a linear regression of the data points.

Work done by Maherani et al. [150] who investigated the temperature dependency of the
permeability of DPPC-liposomes to calcein provides data from which the activation energy for
diffusion was calculated to be 51 kJ/mol. Although this activation energy is approximately 50%
lower than what we deduced in our experiments, it is quite significant and thus casts doubt upon
the first above-mentioned hypothesis. To illustrate the significance of this difference, at 15 min
of incubation, Maherani et al. reported just over 1% release of calcein at 50°C, whereas in this
work just over 20% release was observed at 49°C after 15 min. This is 20-fold faster release than
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published data of liposomes with no internal PFC droplets. Therefore, although the data
apparently fits Eq. 5-1, the value of the activation energy is so high that it is unlikely that this is
the sole or even primary mechanism of calcein release.

5.3.2

Membrane Transition Temperature
As for the second postulate, several studies have shown that liposome permeability has a

local maximum at the lipid melting transition temperature, so an increase in calcein release as a
result of membrane transition would show a maximum at the transition temperature on a plot of
rate vs. temperature [151, 152]. The membrane melting transition temperature for DPPC is 41°C
[150]. As seen in Figure 8, the data do not have a maximum release at the transition temperature
that would be expected if release was solely based on membrane transition and if there were
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Figure 8. Plot of initial fractional calcein release rates versus temperature. The dotted vertical
line represents the literature value of the transition temperature for DPPC (41°C). The solid line
is a representation of expected changes in membrane permeability [151] for passive transport
across phospholipid bilayers. The points are the experimental data.
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changes in membrane diffusivity as it changed from gel to liquid crystal states of the bilayer. The
rate actually appears to increase exponentially as a function of temperature (See Figure 7).
Therefore, it is also unlikely that the membrane transition of the phospholipids is the sole
mechanism of calcein release.

5.3.3

Homogeneous Nucleation
The third postulate consists of gas bubble nucleation above the normal boiling point and

involves fairly complex theory. Firstly, the apparent boiling point of the PFC5 droplet increases
due to the additional pressure imposed by the Laplace pressure (∆𝑃𝑃𝐿𝐿𝐿𝐿 ). The Laplace pressure is
an additional pressure imposed on the interior of a sphere due to the curved interface, and is a
function of the interfacial energy (𝛾𝛾) and the radius (𝑅𝑅) of the emulsion droplet: ∆𝑃𝑃𝐿𝐿𝐿𝐿 =

2𝛾𝛾
𝑅𝑅

. The

total pressure of the emulsion droplet is the sum of atmospheric pressure (𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎 ), the hydrostatic

pressure (𝑃𝑃ℎ𝑦𝑦𝑦𝑦 ), and the Laplace pressure. If gas nucleation sites are present, a gas bubble may

form when the total pressure inside the nanoemulsion (left side of Eq. 5-2) drops below the local
vapor pressure:
(5-2)

𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎 + 𝑃𝑃ℎ𝑦𝑦𝑦𝑦 + ∆𝑃𝑃𝐿𝐿𝐿𝐿 ≤ 𝑃𝑃𝑣𝑣𝑣𝑣𝑣𝑣 (𝑇𝑇)

Ignoring any hydrostatic pressure (ρgΔh), if one takes the interfacial energy of the phospholipidcoated PFC nanoemulsion to be 3.8 dyn/cm [153], and a nanoemulsion with a diameter of 100
nm, the boiling point will increase from 29°C to approximately 57°C. If the droplet were 200 nm,
the apparent boiling point would only be 45 °C. Emulsions for this study may range from 100
nm or lower to about 200 nm in diameter; therefore, the first bubble could form once the
temperature reached somewhere between 45°C to 57°C, with more bubbles likely to form as the
temperature increases.
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However, nucleation must also occur in order for a gas phase to be formed. According to
homogeneous nucleation theory, the number of nucleation events occurring at a given
temperature for a given unit volume per unit time can be approximated with the following
equation:
−𝐸𝐸

(5-3)

𝐽𝐽(𝑇𝑇) = 𝐽𝐽𝑜𝑜 exp(𝑘𝑘 𝑇𝑇𝑐𝑐 )
𝑏𝑏

where 𝐽𝐽𝑜𝑜 is a proportionality constant that has a weak dependence on temperature, 𝐸𝐸𝑐𝑐 is the

activation energy barrier for the formation of a nucleating cavity of a critical radius (𝑟𝑟 ∗ ), and 𝑘𝑘𝑏𝑏

is Boltzmann’s constant [154]. A derivation of 𝐽𝐽(𝑇𝑇) is given in Section 5.3.3.1. If we assume that
the release rate of calcein is proportional to the number of nucleation events occurring, then the
two events (nucleation and release) should follow the same trend. As seen in Figure 9, this is
somewhat observed. The nucleation of gas bubbles begins about 10°C above the apparent boiling
point. The nucleation rates increase exponentially at first and then continue to increase linearly.
While the trends of homogeneous nucleation theory and the experimental data somewhat match,
the experimental data begin to increase at an earlier temperature than homogeneous nucleation
theory indicates. This suggests that there are emulsion droplets much larger than 200 nm, or that
the theory is not sufficient.
Mountford and Borden investigated the spontaneous vaporization of 800 nm
perfluoropropane (PFC3) and perfluorobutane (PFC4) droplets. Their results indicate that
although the release of calcein appears to coincide with the boiling point of 100-200 nm PFC5
droplets adjusted for local Laplace pressure (45-57°C), spontaneous vaporization of PFC
droplets occur at approximately 90% of the critical temperature (𝑇𝑇𝑐𝑐 ) [67]. According to

Mountford and Borden, spontaneous vaporization of PFC5 should occur at approximately 107°C
(𝑇𝑇𝑐𝑐 =423.1K, [71]). In our experiments, calcein release is seen at a much lower temperature than
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can be explained by homogeneous nucleation, therefore we turn to heterogeneous nucleation
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Figure 9. Plot of initial fractional calcein release rates (left axis) and rate of nucleation
events (right axis) versus temperature. The points indicate the experimental data and
correspond to values on the left axis. The dotted line (d = 200 nm) and solid line (d = 100
nm) are theoretical homogeneous nucleation data and correspond to values on the right axis.

5.3.3.1 Derivation for Homogeneous Nucleation
The following derivation was used to provide the theoretical homogeneous nucleation
data shown in Figure 9. Blander [155] provides a derivation for obtaining the nucleation rate, 𝐽𝐽,
for homogeneous nucleation in the form shown in Eq. 5-3. 𝐽𝐽𝑜𝑜 is a proportionality constant

assumed to be the number density of the liquid and is given by the following equation
2𝛾𝛾𝑔𝑔 1/2

(5-4)

𝐽𝐽𝑜𝑜 = 𝑁𝑁 � 𝜋𝜋𝜋𝜋 �

where 𝛾𝛾𝑔𝑔 is the interfacial energy of the gas bubble with radius 𝑟𝑟 ∗ , 𝑁𝑁 is the number density
(molecules/m3) of liquid PFC5, and 𝑚𝑚 is the molecular mass of PFC5 [154].
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The interfacial energy is a function of temperature and was taken from the DIPPR
database [71]. The dependence on temperature for 𝐽𝐽𝑜𝑜 is weak compared to the terms inside of the
exponent in Eq. 5-3.

There are two factors that contribute to the energy required (𝐸𝐸) to form a gas cavity
within a liquid droplet: 1) surface energy of the cavity formed, and 2) free energy change during
vaporization. The surface energy of the nucleus formed is calculated as the interfacial energy of
the gas bubble, 𝛾𝛾𝑔𝑔 , multiplied by its surface area, 4𝜋𝜋𝑟𝑟 2, where 𝑟𝑟 is the radius of the gas bubble.
The free energy change during vaporization can be accounted for by the free energy of
4

vaporization, ∆𝐺𝐺𝑣𝑣 , of the entire vapor bubble: 3 𝜋𝜋𝑟𝑟 3 ∆𝐺𝐺𝑣𝑣 . The energy required to form a gas

cavity with radius, 𝑟𝑟, is
4

𝐸𝐸 = 3 𝜋𝜋𝑟𝑟 3 ∆𝐺𝐺𝑣𝑣 + 4𝜋𝜋𝑟𝑟 2 𝛾𝛾𝑔𝑔 .

(5-5)

The first term on the right hand side of Eq. 5-5 is negative at temperatures above the apparent
boiling point of the PFC5 nanoemulsion, and is the driving force for nucleation. The second term
on the right hand of the equation is always positive. The critical radius, 𝑟𝑟 ∗ , is the radius of the

bubble when 𝐸𝐸 is at a maximum. Differentiating Eq. 5-5 with respect to 𝑟𝑟 and setting it equal to
zero provides a value for 𝑟𝑟 ∗ (after rearranging):
𝑟𝑟 ∗ =

−2𝛾𝛾𝑔𝑔
∆𝐺𝐺𝑣𝑣

.

(5-6)

∆𝐺𝐺𝑣𝑣 can be obtained from the following equation
∆𝐺𝐺𝑣𝑣 = ∆𝐻𝐻𝑣𝑣 − 𝑇𝑇∆𝑆𝑆𝑣𝑣

where ∆𝐻𝐻𝑣𝑣 is the latent heat of vaporization, and ∆𝑆𝑆𝑣𝑣 is the change in entropy during

(5-7)

vaporization. For a pure liquid in equilibrium with its vapor phase at constant temperature and
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pressure, the free energy of the vapor phase is equal to the free energy of the liquid phase.
Therefore, at equilibrium and the apparent boiling point, 𝑇𝑇𝑣𝑣 ,
∆𝐻𝐻𝑣𝑣

∆𝑆𝑆𝑣𝑣 =

𝑇𝑇𝑣𝑣

.

(5-8)

Assuming that ∆𝑆𝑆𝑣𝑣 does not change much with temperature above the apparent boiling point,
Eqs. 5-7 and 5-8 can be combined to yield
𝑇𝑇𝑣𝑣 −𝑇𝑇

∆𝐺𝐺𝑣𝑣 = �

𝑇𝑇𝑣𝑣

� ∆𝐻𝐻𝑣𝑣 .

(5-9)

The latent heat of vaporization can be obtained from the Clapeyron Equation,
𝑑𝑑𝑃𝑃𝑣𝑣
𝑑𝑑𝑑𝑑

∆𝐻𝐻

(5-10)

𝑣𝑣
= 𝑇𝑇(𝑉𝑉 −𝑉𝑉
𝑣𝑣

𝐿𝐿 )

where 𝑃𝑃𝑣𝑣 is the corresponding pressure of the vapor phase in equilibrium with the liquid

nanoemulsion droplet, and (𝑉𝑉𝑣𝑣 − 𝑉𝑉𝐿𝐿 ) is the change in volume accompanying the change from

liquid (𝑉𝑉𝐿𝐿 ) to vapor phase (𝑉𝑉𝑣𝑣 ). 𝑉𝑉𝐿𝐿 was assumed to be constant and was obtained from the DIPPR

database [71]. Assuming the vapor phase is an ideal gas, 𝑉𝑉𝑣𝑣 can be written as
𝑅𝑅𝑔𝑔 𝑇𝑇

𝑉𝑉𝑣𝑣 = �

𝑃𝑃𝑣𝑣

�

(5-11)

where 𝑅𝑅𝑔𝑔 is the universal gas constant. Assuming the 𝑃𝑃𝑣𝑣 in Eq.5-11 is constant and equivalent to
the pressure inside the emulsion droplet, it can be defined as

(5-12)

𝑃𝑃𝑣𝑣 = 𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎 + 𝑃𝑃ℎ𝑦𝑦𝑦𝑦 + ∆𝑃𝑃𝐿𝐿𝐿𝐿

where 𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎 is the atmospheric pressure, 𝑃𝑃ℎ𝑦𝑦𝑦𝑦 is the hydrostatic pressure, and ∆𝑃𝑃𝐿𝐿𝐿𝐿 is the Laplace

pressure. 𝑃𝑃ℎ𝑦𝑦𝑦𝑦 was neglected for this analysis, and ∆𝑃𝑃𝐿𝐿𝐿𝐿 is defined as
∆𝑃𝑃𝐿𝐿𝐿𝐿 =

−2𝛾𝛾𝐿𝐿𝐿𝐿
𝑅𝑅𝑒𝑒𝑒𝑒
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(5-13)

where 𝛾𝛾𝐿𝐿𝐿𝐿 is the interfacial energy of the nanoemulsion liquid and the phospholipids, and 𝑅𝑅𝑒𝑒𝑒𝑒 is
the radius of the PFC5 nanoemulsion droplet. The value of 𝛾𝛾𝐿𝐿𝐿𝐿 used in this analysis was 3.8
dyne/cm2 [153].

The apparent boiling point, 𝑇𝑇𝑣𝑣 , was determined by finding the temperature that

corresponds to the 𝑃𝑃𝑣𝑣 calculated in Eq.5-12 and using the DIPPR [71] vapor pressure correlation.

This function was differentiated with respect to 𝑇𝑇 and combined with Eqs. 5-10-13 to yield the

following equation:

𝑇𝑇𝑣𝑣 −𝑇𝑇

∆𝐺𝐺𝑣𝑣 = �

𝑇𝑇𝑣𝑣

𝑅𝑅𝑔𝑔 𝑇𝑇

� 𝑇𝑇 �2𝛾𝛾𝐿𝐿𝐿𝐿

�𝑅𝑅
𝑒𝑒𝑒𝑒

− 𝑉𝑉𝐿𝐿 �

𝑑𝑑𝑃𝑃𝑣𝑣
𝑑𝑑𝑑𝑑

.

(5-14)

∆𝐺𝐺𝑣𝑣 is a function of both the local temperature and the size of the nanoemulsion droplet. The

critical radius, as a function of temperature, can now be calculated by inserting Eq.5-14 into

Eq.5-6. 𝐸𝐸𝑐𝑐 is defined as the activation energy at 𝑟𝑟 ∗ , obtained by inserting 𝑟𝑟 ∗ in Eq.5-5. Now

𝐽𝐽(𝑇𝑇) (see Eq. 5-3) can be plotted as a function of temperature using the derivation above, and is
plotted in Figure 9 as the theoretical homogeneous nucleation data. Apparently homogeneous

nucleation does not fit the data since release of calcein appears to occur at temperatures lower
than homogeneous nucleation predicts. So we turn to heterogeneous nucleation to look for a
better theory to fit the data.

5.3.4

Heterogeneous Nucleation
It is impossible to have homogeneous nucleation of a liquid at its equilibrium boiling

point because the gas bubbles are unstable and will collapse spontaneously [155]. Therefore,
nearly all experimentally formed gas bubbles are nucleated on surfaces of impurities in the
system. Brennen [154] points out that the homogeneous nucleation is exceedingly difficult to
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obtain in the laboratory because even carefully distilled solvent still contains solid or dissolved
chemical contaminants. The presence of contaminating particulates in the PFC5 emulsion would
present sites for nucleation leading to heterogeneous nucleation. The extent to which a
particulate can lower the activation energy for heterogeneous nucleation depends upon the
contact angle of the nucleating agent on the contaminant surface [156]. Lower contact angles
will result in a lower energy barrier. The activation energy for heterogeneous nucleation is lower
than the activation energy for homogeneous nucleation; therefore, nucleation will happen at
lower temperatures in heterogeneous nucleation. For example, homogeneous nucleation (see
Section 5.3.3 and 5.3.3.1 and Figure 9) predicts 0 (or at least less than 10-15) nucleation events per
nm3 per second at 49°C for a 200-nm PFC5 emulsion droplet; whereas heterogeneous nucleation
(see Figure 10 and Section 5.3.4.1) predicts about 1011 nucleation events per nm3 per second at
49°C for a 200-nm PFC5 emulsion droplet. Using the same derivation for homogeneous
nucleation (see 5.3.3.1), but using only a fraction of the interfacial energy of the nanoemulsion
droplet, it is possible to fit the trend in the data to the theory for nucleation at temperatures above
the adjusted boiling point (Figure 10).

5.3.4.1 Derivation for Heterogeneous Nucleation
For heterogeneous nucleation, the possible contaminants in the liquid phase provide a
nucleation site and therefore reduce the energy required for nucleation. Depending on the
mechanism, the energy required to create a nucleating gas phase is lowered. This is often
attributed to a lower energy associated with forming the gas-liquid interface. To account for this
reduction in surface energy required, we simply employed a scale factor, 𝑓𝑓, to the surface energy
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Figure 10. Plot of initial fractional calcein release rates (left axis) and rate of nucleation
events (right axis) versus temperature. Experimental data (points) correspond to values on
the left axis. Theoretical heterogeneous nucleation of 200 nm droplets (line) corresponds
to values on the right axis.

term to determine the 𝐸𝐸𝑐𝑐 for heterogeneous nucleation. At the critical radius, 𝑟𝑟 ∗ , Eq. 5-5
then becomes

4

3

2

𝐸𝐸𝑐𝑐 = 3 𝜋𝜋𝑟𝑟 ∗ ∆𝐺𝐺𝑣𝑣 + 4𝜋𝜋𝑟𝑟 ∗ 𝛾𝛾𝑔𝑔 𝑓𝑓

(5-15)

Using Eq. 5-15 in Eq. 5-3, the value of 𝑓𝑓 to fit the experimental data shown in Figure 10 was

found to be 𝑓𝑓 = 0.6678. It should be noted that this equation is only valid for temperatures above
the apparent boiling point or the boiling point adjusted for the local Laplace pressure.

Heterogeneous nucleation theory (Figure 10) predicts that nucleation events happen at the lower
temperatures where calcein release was observed (i.e. 49°C), whereas homogeneous nucleation
theory (𝑓𝑓 = 1, dotted line in Figure 9) predicts that nucleation will not occur.

5.4

Conclusions
The analysis presented above suggests that, of the several possible causes of calcein release

from the liposomes containing nanosized PFC5 droplets, we can rule out some possibilities, and
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perhaps accept others. The calcein release data do not fit what would be expected for
temperature-induced changes in DPPC membrane permeability as heating caused a change from
the solid-gel phase of the bilayer membrane to the liquid crystal phase. Others have observed a
maximum in permeability right at the transition temperature [151], which would be 41°C in this
study. Thus, we will dismiss this possibility as a major contributor, although this could possibly
be happening in a small degree while other mechanisms dominate.
Likewise, we can dismiss a simple thermal increase in diffusion of calcein through the
DPPC bilayer. According to Eq. 5-1, higher temperatures should result in a faster diffusion
through the liposomal bilayer. While greater release rates of calcein at higher temperatures is
seen (Figure 7), the very high activation energy predicted for diffusion casts doubt on diffusion as
a major mechanism for calcein release.
Homogeneous nucleation theory predicts that the release of calcein temperature would
occur at higher temperatures than observed; and this rarely occurs except in highly purified and
controlled experiments. Mountford and Borden point out that the temperature must approach
~0.9 (107°C for PFC5 [71]) of the critical temperature for spontaneous vaporization of PFC
droplets. Calcein release occurs at temperatures much lower than suggested by the vaporization
of PFC5 droplets as a result of homogeneous nucleation.
Heterogeneous nucleation theory was able to capture the general shape and trends observed
experimentally, but definitive proof is lacking. Heterogeneous nucleation could be caused by a
variety of sources, such as micelles of DPPC in the PFC5 droplets, solid contaminants in the
PFC5 droplets, or even dissolved oxygen or nitrogen in the PFC5.
As will be shown in Chapter 7, we have strong evidence for heterogeneous nucleation of gas
bubbles when doxorubicin sulfate crystals are formed inside the liposomes; but there is no
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doxorubicin in these experiments employing calcein. The most important finding from these
experiments is that the DPPC liposomes containing PFC5 emulsions and calcein are stable at
body temperature (37°C), even though this temperature is above the normal boiling point of
PFC5 (29°C).
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6

6.1

GOLD NANORODS

Introduction
Gold nanoparticles are a promising new nanotechnology with a wide variety of biomedical

applications including hyperthermia [44, 45], imaging [46-48], and controlled release of
therapeutics [46, 49]. In all of these biomedical applications, lasers are used to heat the
nanoparticles, which in turn heat their surroundings to produce a therapeutic or diagnostic
response. The lasers typically operate at a wavelength in the near-infrared (NIR) window (650900 nm) [43] because hemoglobin and water have their lowest absorption coefficients in this
region and the laser can therefore penetrate deeper in the tissues. One of the major benefits of
gold nanoparticles, particularly gold nanorods (GNRs), is that they can be synthesized to absorb
laser light in the NIR window. Other optimal properties of gold nanoparticles in biomedical
applications include gold being non-toxic, the relative ease of attaching some ligands to the gold
surface, and the efficiency of gold emitting heat from irradiated laser-lights.
Gold nanorods were chosen in the current research because of the ability to tune the
wavelength of maximum absorbance to the wavelength of our laser by adjusting the length and
radius of the gold nanorod. GNRs have 2 maximums in their absorbance corresponding to the
plasmon resonance of the electrons around the length and width of the nanorod. The aspect ratio
of the nanorod (length/width) can be changed by slight variations in the synthesis process. The
larger the aspect ratio is, the larger the wavelength is for the maximum absorbance peak. The
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desired aspect ratio to obtain a maximum absorbance wavelength around 785 nm is about 3.8
[157]. Gold nanorods also demonstrate the highest efficiency of converting laser irradiation to
heat with an absorption cross section over 13 times larger than its geometrical cross section
[158]. The geometrical cross section is the physical area of the nanorod that intercepts irradiated
light from the laser, whereas the absorption cross section is the area corresponding to the
effective area of light absorbed due to the plasmon surface resonance.
The goal of this research was to place gold nanorods inside of perfluoropentane (PFC5)
emulsion droplets, which were then encapsulated inside of liposomes. These eLiposomes would
then be loaded with a therapeutic and when the laser heated the gold nanorods, the emulsion
droplet would vaporize and form a large gas bubble, which would break open the liposome and
release the therapeutic. The desired application would be to release the therapeutic using a
wearable and portable laser device. This type of application would provide an optimal
opportunity for an individual undergoing chemotherapy to have controlled release of a
therapeutic, without the negative side effects of a systemic release, from the comfort of one’s
own home, or even while at work.

6.2

Surface Modification
The first step in obtaining GNR loaded PFC5 emulsion droplets was to synthesize the

nanorods and modify their surface chemistry. GNRs were synthesized with a coating of cetyl
trimethyl ammonium bromide (CTAB) which is toxic to the body in µM amounts when freely
administered. Since CTAB is not covalently bound to the GNR it would eventually desorb from
the gold nanorod into the body in toxic amounts [159]. For this reason CTAB is commonly
replaced with a PEGylated thiol [52], in which the stronger covalent bond (Au-S) replaces the
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ionic bonding of CTAB to gold without changing the GNR shape. Another method of reducing
cytotoxicity from desorbing CTAB is to encapsulate the CTAB-coated GNR in a shell (often a
silica shell) without actually removing the CTAB [160].
The surface of GNRs were also modified in order to transfer GNRs from water into
PFC5. GNRs were synthesized to be hydrophilic and freely suspended in an aqueous solution
and would not transfer to PFC5 without first modifying the surface of the GNRs. There are
investigators who are currently researching how to transfer GNRs to an organic media [161-163].
As mentioned, some investigators simply encase the GNRs (CTAB included) with a silica shell,
as that process is easier than replacing the CTAB. The silica shell can then be derivatized to
make the surface hypdrophobic. While this method is effective in transferring the GNRs to an
organic media, the silica shell will act as a thermal insulator, thus requiring more energy to heat
the silica surface sufficiently to vaporize the surrounding perfluorocarbon droplet. One group
reports a successful transfer of GNRs to perfluoropentane using both a thiol replacement [59]
and encapsulation of the GNRs in silica [47], but there are no reports of drug delivery using this
construct.
In our lab, gold nanorods were synthesized (Figure 11) according to slightly modified
published procedures [140]. The established procedures were modified to obtain a maximum
absorbance wavelength around 785 nm, the operating wavelength of our laser. Briefly, a seed
solution was made by mixing 5 mL of HAuCl4 (0.5 mM ) with 5 mL of CTAB, followed by the
addition of 600 µL of ice cold NaBH4 (0.01 M). A growth solution was prepared by mixing 0.28
mL of AgNO3 (0.004 M) with 5 mL of CTAB and 5 mL of HAuCl4 (1 mM). 70 μL of ascorbic
acid (0.0788 M) was then added to the growth solution which resulted in a clear, colorless
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solution. 13.35 μL of the seed solution was then added to the growth solution and stirred for 2
min before being left in a 28°C water bath overnight.

Figure 11. TEM image of GNRs synthesized in our lab.

After GNRs were synthesized, a slightly modified procedure from Wilson et al. [59] (see
Section 4.2.2.2) was used to replace the CTAB with thiolated polyethylene glycol (mPEG-SH)
and pefluorodecanethiol (PFD-SH). This procedure was difficult to reproduce in that it was not
always successful in resuspending the GNRs in PFC5. Communications with Katherine Wilson
confirmed that the transfer of GNRs to PFC5 did not always work well, but it was good enough
for what she was attempting to do. My purpose in transferring GNRs to PFC5 was to vaporize
the PFC5 through laser-induced heating of the GNRs. A change from clear to a pink opaque
PFC5 phase indicated a resuspension of GNRs in the PFC5. The PFC5 emulsions with GNRs
were suspended in thin capillary tubes and irradiated with a 450 mW continuous wave (cw) laser,
as well as a pulsed laser. Samples were incubated at 37 °C for the irradiation with the cw laser,
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while samples were kept at 37 °C until immediately before irradiation with the pulsed laser. No
detectable vaporization of the emulsion droplets was observed with irradiation from either laser.

6.3

Laser-induced Heating
Heating of gold nanorods occurs when photons from the laser excite the electrons of the

gold nanorods, and the electrons then heat the gold lattice, which dissipates the heat to its
surrounding medium. All of this heating occurs on the order of femtoseconds to picoseconds.
When heating at the nanoscale, one important concept to understand is thermal confinement,
which occurs when the laser pulse duration is less than the thermal relaxation time for the
irradiated volume. This relaxation time (𝜏𝜏) can be estimated using the following equation
𝜏𝜏 =

𝑟𝑟 2

(6-1)

𝛼𝛼

where 𝑟𝑟 is the particle radius, and 𝛼𝛼 is the thermal diffusivity of the surrounding medium. An

effective radius (𝑟𝑟𝑒𝑒𝑒𝑒𝑒𝑒 ) is used for a GNR, which is equal to the radius of a sphere of equivalent
volume. For a 10 nm x 40 nm rod (𝑟𝑟𝑒𝑒𝑒𝑒𝑒𝑒 = 9.1 nm) in water (𝛼𝛼 = 1.47 x 10-7 m2/s), the

corresponding relaxation time is approximately 0.56 ns. This suggests that the rod will heat up to
a high temperature and cool down to the initial temperature of its surroundings after
approximately 3 x 𝜏𝜏, or 1.7 ns. This allows for quick and significant heating of GNRs with a high
powered fs pulsed laser.

The steady state temperature (𝑇𝑇𝑠𝑠𝑠𝑠 ) of a single gold nanoparticle irradiated by a laser in

which the laser pulse duration is significantly longer than the thermal relaxation time is given by
𝑇𝑇𝑠𝑠𝑠𝑠 − 𝑇𝑇∞ =

𝐼𝐼𝐶𝐶𝑎𝑎𝑎𝑎𝑎𝑎

(6-2)

4𝜋𝜋𝜋𝜋𝑟𝑟𝑛𝑛𝑛𝑛
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where 𝑇𝑇∞ is the temperature of the liquid surrounding the gold nanoparticle, 𝐼𝐼 is the laser

fluence (W/m2), 𝐶𝐶𝑎𝑎𝑎𝑎𝑎𝑎 is the absorption cross section of the nanoparticle, 𝑘𝑘 is the thermal

conductivity of the liquid, and 𝑟𝑟𝑛𝑛𝑛𝑛 is the characteristic radius of the nanoparticle. While this

equation is developed for a sphere, the effective radius (𝑟𝑟𝑒𝑒𝑒𝑒𝑒𝑒 ) can be used to estimate heating
from gold nanorods. In order for a nucleation event to occur, the liquid interface of the gold

nanorod surface must reach a sufficiently high temperature, perhaps as high as 0.9 x 𝑇𝑇𝑐𝑐 (critical
temperature). The governing equation for the gold nanoparticle-medium interface is given by

(6-3)

𝐼𝐼𝐶𝐶𝑎𝑎𝑎𝑎𝑎𝑎 = 𝐺𝐺𝐺𝐺(𝑇𝑇𝑠𝑠𝑠𝑠 − 𝑇𝑇𝑚𝑚𝑚𝑚𝑚𝑚 )

where 𝐺𝐺 is a thermal conductance at nanoparticle-liquid interface, 𝐴𝐴 is the geometrical cross

section, and 𝑇𝑇𝑚𝑚𝑚𝑚𝑚𝑚 is the temperature of the fluid or solid material at the nanoparticle interface.
Rearranging Eq. 6-3 to solve for 𝑇𝑇𝑠𝑠𝑠𝑠 and substituting the equality into Eq. 6-2 (noting the

direction of heat flow), the required fluence necessary to increase the temperature of the liquid at
the nanoparticle interface can be determined. Since the value of G (105.0 x 106 W/m2 K) has
been reported for GNRs in water [164] the results of this calculation is given in Figure 12 for the
heating of single GNR in water using the property values given in Table 1. It should be noted
that to raise the temperature at the surface of the water just 1 K requires a laser fluence that is 3
orders of magnitude higher than the laser fluence used in current in vivo medical therapy [158].
This high energy requirement to heat a single GNR occurs because of the rapid heat dissipation
from the GNR due to the large surface to volume ratio of this nanoparticle, and the very small
value of 𝑟𝑟.
Table 1. Gold nanorod properties and gold nanorod-water interface properties used in calculating fluences
in Figure 12.
Size

λspra (nm)

Cabs (nm2)
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𝐴𝐴 (nm2)

kb (W/m K)

Gc (W/m2 K)

Width = 13 nmd
Length = 49 nmd
reff = 11.58 nm
a
c

797d

5674d

421

0.613

105.0 x 106e

Suface plasmon resonance wavelength (maximum absorbance), b thermal conductivity of water,
thermal conductance of water-gold interface, d from [165], e from [164]
2.50E+06

Fluence (W/cm2)

2.00E+06
1.50E+06
1.00E+06
5.00E+05
0.00E+00

0

5

10

15

20

25

ΔT (°C)
Figure 12. Fluence required to heat water at the interface of a single GNR using a
cw laser.

Besides increasing the laser fluence of a cw laser, pulsed lasers (ns and fs) can be used to
achieve significant temperature increases within the GNR. There is a caution, though, with
delivering too much energy to a GNR via a pulsed laser. The GNR can melt if its temperature
rises above its melting point (1336 K); and when it solidifies again it will no longer be in the
shape of a rod, drastically changing the maximum absorbance wavelength. This caution does not
apply to typical cw lasers, but for pulsed lasers (where the pulse length is closer to or shorter
than the relaxation time) it can present a problem. Attia et al. [166] observed no physiological
changes or changes in absorption when GNRs were irradiated with a cw laser; however, they
observed melting of the GNRs and a significant change in absorption when irradiated with a
pulsed laser. Although cw lasers used in in vivo applications do not have enough power to
significantly raise the temperature of a single GNR, cw lasers can cause a significant heating
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effect when there is collective heating due to a large number (109/mL) of GNRs in a relatively
large region. To illustrate, Maltzahn et al. [167] administered 14 x 47 nm PEGylated GNRs (20
mg/kg) to tumor-bearing mice; and with ~7% ID/g (injected dose/gram of tissue, 1011 GNRs/mL
in an assumed 21-gm mouse) accumulation of GNRs at the tumor site, they observed a 40K
increase in temperature at the irradiated tumor site (810 nm, 2 W/cm2, 5 mm laser beam size, 5
min). Although the collective heating of gold nanorods using a cw laser can significantly heat the
media surrounding GNRs, we did not observe vaporization of our GNR-loaded PFC5 emulsion
droplets using a cw laser or a pulsed laser.

6.4

Discussion
Possible reasons for failure to vaporize PFC5 emulsion droplets in our experiments include

an inadequate transfer of GNRs to the PFC emulsion droplets and not enough laser energy
delivered to vaporize the emulsion droplets. A recent article [47] by the same group as Wilson et
al. (see Section 6.2) used a different, more efficient, method for transferring GNRs to PFC5. In
this method they fluorinated the rods with 1H,1H,2H,2H-perflourodecyl-triethoxysilane, which
forms a silica shell around the surface of the rods. The CTAB is not replaced before the addition
of the fluorinated silane. While this method proved effective at transferring GNRs to PFC5 and
even in imaging with lasers, the energy required for vaporization is not feasible with a portable
and wearable device.
Pulsed lasers can easily deliver enough laser energy to vaporize a GNR loaded PFC5
droplet. The study by Wilson et al. [59] used PFC5 droplets (200 nm diameter) loaded with 2-15
GNRs, and they were able to see vaporization of the droplets using a pulsed laser (5.0 mJ/cm2
pulse energy, 10 Hz pulse repetition rate and 5-7 ns pulse length for 60 s; 5.0mJ/cm2 delivered in
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6-ns pulses is equivalent to 8.3 x 105 W/cm2 per pulse). Hannah et al. [47] never mentioned the
number of GNRs/droplet or showed a crytoTEM image of their GNR loaded droplets. The
droplets used in their experiments were 200-800 nm in diameter, and they used a pulsed laser
delivering laser light at fluences of up to 90 mJ/cm2 (Nd:YAG, 1064 nm, 27 mm2 spot size,
unknown pulse length). They noticed the photoacoustic signal as a result of vaporization
immediately after pulsed laser irradiation (t = 0.5s). A signal was observed at fluences as low as
4 mJ/cm2, but only with the largest droplets. Our work presented in Section 6.2 used smaller
droplets and lower fluences than those used by Hannah et al. Their results highlight a few of the
factors required for vaporization of the droplets including the size of the droplets and the
required fluence. While pulsed lasers can deliver enough laser energy to heat GNRs sufficiently
to vaporize relatively small PFC5 nanodroplets, pulsed lasers are too large to wear as a
therapeutic device.
The calculated results shown in Figure 12 suggest that portable cw lasers, which might
have at most 1 W cw power, do not have sufficient power to heat a single GNR to induce a phase
change in a PFC5 droplet. The question remains as to whether multiple gold nanorods in PFC5
emulsion droplets can produce enough of a collective heating to trigger the nucleation of a PFC5
vapor bubble with a wearable cw laser. Liu et al. [58] showed a crytoTEM image of their GNR
loaded PFC droplets which show 2 GNRs in the droplet. Their droplets were formed by mixing
HSA with ice-cold PFC5 droplets and sonicating the solution. Liu et al. used a 2.6 W cw laser to
vaporize 220-340 nm PFC5 droplets containing GNRs. It should be noted that a 2.6 W cw laser
is in the most dangerous class of lasers and will leave scars and damage skin when administered.
As such, it would not be approved to be a portable device for a patient to wear as they obtain
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treatment. However, Liu et al. did notice the vaporization of the PFC5 droplets and significant
heating of the tumor sites after 5 min of laser irradiation using a cw laser.
The majority of studies investigating GNR heating to cause vaporization of a droplet use
a pulsed laser to concentrate enough power to heat the GNR sufficiently to vaporize the droplet.
These studies are interested in the acoustics of vaporization for diagnostic purposes, and the
large amount of power delivered in nanosecond to femtosecond pulses is enough to vaporize the
droplets. Most studies using a cw laser and GNRs are using the GNR heating to produce a local
hyperthermia, not to vaporize droplets. Liu et al. [58] mentioned above did use a cw laser to
initially vaporize PFC droplets; however, they also used the GNRs to heat the tumor site. For
local hyperthermia, the goal is to have a sustained temperature between 40-45 °C [168].
Continuous wave lasers are better for the longer time associated with local hyperthermia because
the lower amount of energy delivered will do less damage to heathy tissue compared to high
power pulses for a sustained period of time.

6.5

Conclusion
Our objective in attempting laser-induced GNR heating was to have a portable and wearable

laser to vaporize nanodroplets. The pulsed lasers used for nanodroplet vaporization are not
portable or wearable. The cw lasers that are safely portable do not provide enough energy to
vaporize the nanodroplets. While the future may still hold the possibility of a wearable device,
we concluded investigating GNR heating via lasers and moved on to investigating ultrasound as
a means to actuate the release of therapeutics from liposomes.
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7

7.1

CYTOSOLIC DELIVERY OF DOX USING ELIPOSOMES

Introduction
Cancer drugs that are not delivered inside of a carrier (free drug) often have a relatively

low bioavailability in tumors unless administered in very high doses [169]. One reason for the
low bioavailability of free drugs is that they are rapidly cleared from the blood. For example, free
doxorubicin (Dox) has a distribution half-life of 3.6 min, whereas Doxil (a PEGylated liposome
loaded with Dox) has a distribution half-life of over 50 hours [170]. PEGylation of the liposomes
avoids clearance by the reticuloendothelial system (RES). Therefore, PEGylated liposomes are
often used as drug carriers in order to increase the circulation time of cancer drugs.
Liposomes will only be a benefit in cancer drug delivery if the drug is released at or inside
the tumor cells, thus increasing the drug concentration at the tumor site and decreasing the drug
concentration around healthy tissue. Gabizon et al. [20] reported that there is minimal release of
Dox (<2%) during circulation of Doxil, and therefore Dox is initially delivered to the tissues
while still inside of a liposome. This work does not study how the liposomes get to the tumor
site, but how the drug is released once the liposomes arrive at the targeted location. Liposomes
can be “targeted” to cancer cells by attaching a ligand to the surface of the liposomes, which
corresponds to a receptor found on the surfaces of the cancer cells. The ligand on the liposome
does not act like a homing missile targeted at cancer cells (which implies swimming against the
current and crossing barriers), but more like one half of a piece of Velcro with the other half
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being found more frequently on the surface of cancer cells compared to healthy cells. The
targeting of cancer cells, therefore, is only as good as the specificity of the ligand for receptors
on the surface of cancer cells and does not occur instantly when the liposomes are injected. The
liposomes build up in the tissues over time.
Folate is the targeting ligand of choice in this work because it is overexpressed on over 1/3
of cancer cells [6], and it is relatively inexpensive to use as a model ligand. Furthermore, folate
will induce endocytosis once the ligand is bound by a receptor on the surface of a cell. Once
taken in by the cell, the drug will still need to escape from the liposome and the endosome
(cellular vesicle surrounding the liposome after endocytosis). A higher concentration of drugs
can be achieved inside the cell cytosol if there is a release mechanism that can be activated after
endocytosis rather than traditional release outside the cell followed by diffusion into the cell. The
objective of study in this chapter is to determine the efficacy of using ultrasound (US) to control
the release of Dox from eLiposomes in order to enhance the killing of multidrug-resistant (MDR)
cancer cells.
Cancer cells that survive exposure to cancer drugs can develop an acquired resistance to
the administered drugs and to many other types of cancer drugs as well. This undesired
phenomenon is known as multidrug resistance. One of the established mechanisms for multidrug
resistance is the production of an increased number of export pumps [12-15], which will increase
the rate at which undesired compounds inside of the cell (such as cancer drugs) are pumped out
of the cell. We hypothesize that delivery of a significant amount of Dox directly to the cytosol of
a MDR cancer cell will increase both the concentration and the residence time of Dox in the cell
cytosol, and therefore increase the probability that Dox will initiate apoptosis at the nucleus and
kill the MDR cancer cell.
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Previous work in Dr. Pitt’s lab has shown the successful synthesis of eLiposomes [66]
and the controlled delivery of calcein (a model drug) [9, 122] to the cytosol of non-MDR HeLa
cells. Ultrasound-induced vaporization of the emulsion droplet was the method of controlled
release from the liposome, and in the previous work [9] calcein was only observed in the cell
cytosol when US was applied to folated (targeted) eLiposomes loaded with calcein. It is our
desire to use ultrasound as a remote trigger that can induce the expansion of the emulsion droplet
to gas through acoustic droplet vaporization, and thus trigger the release of Dox to the cytosol of
multidrug-resistant cancer cells only where US is focused. The aim of this work, therefore, was
to determine if cytosolic delivery of Dox from folated eLiposomes, triggered by US, will
enhance the killing of MDR cells.

7.2
7.2.1

Results
MCF 7 Cells
Our lab had access to a Dox-resistant breast cancer cell line (MCF7/ADR, kindly donated

from Dr. You Han Bae, University of Utah) as well as a Dox-sensitive breast cancer cell line
(MCF7, kindly donated from Dr. O’Niell, MMBio, BYU). Preliminary results from our lab
indicated no large, significant differences in the killing of these MCF7 cells (sensitive or
resistant) treated with folate-targeted or non-targeted Dox-loaded liposomes. While some
researchers use folate to induce folate-mediated endocytosis in MFC 7 cells [133, 171, 172],
many researchers classify MCF 7 cells as having a low expression of folate receptors [173-175].
We suspected that the lack of response to folation of liposomes was due to the low intrinsic
concentration of folate receptors. Therefore, we obtained a different cell line (KB) which has
significantly higher expression of folate receptors compared to MCF7 cells [136, 174].
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7.2.2

KB Cells
KB cells are a derivative of HeLa cells, a cervical cancer harvested from Henrietta Lacks

in 1951 [134, 135]. These cells were chosen to investigate the cytotoxicity of Dox-loaded folated
eLiposomes (folated eLipoDox) because the KB cells have a higher expression of folate
receptors [136]. Furthermore, both a resistant and sensitive strain of these cells are available.
KB-V1 (Dox resistant) and KB-3-1 (Dox sensitive) cells were a kind gift from Dr. Gottesman
(NIH, Bethesda, MD). The KB-V1 cells have an acquired multi-drug resistance produced from
culturing the cells in an increasing concentration of vinblastine [138]. They are also resistant to
Dox and colchicine while never being exposed to these drugs [138].
Various concentrations of free (soluble) Dox were administered to both KB-V1 and KB3-1 cells to confirm the resistance of the KB-V1 cells to Dox and to determine an optimal
concentration for subsequent experiments with folated eLipoDox. Cell viability was determined
via an MTT assay (see Section 4.2.3.10), a colorimetric assay which measures the cell metabolic
activity. Figure 13 shows that the dose response curve for the MDR KB-V1 cells is shifted to the
right compared to KB-3-1 cells, indicating that the KB-V1 cell line is indeed more resistant to
treatment with free Dox compared to the KB-3-1 cell line. The shift is about 2 log units,
indicating that 100-fold more Dox (external to the cell) is required to produce a similar toxicity
in the MDR KB-V1 cell line even though this cell line had been developed by vinblastine
exposure, thus proving its multidrug-resistant behavior.
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Figure 13. Dose response curve for KB-3-1 and KB-V1 cells treated with Dox. Predicted
values were fit to a four parameter logistic equation using a least square regression
analysis. Error bars represent the standard deviation of experimental data points (n=3).

The Dox IC50 values of KB-3-1 and KB-V1 cells were determined using the following
four parameter logistic equation

𝑌𝑌 = 𝐷𝐷 +

𝐴𝐴−𝐷𝐷

(7-1)

1+10(𝑙𝑙𝑙𝑙𝑙𝑙10 [𝑥𝑥]−𝑙𝑙𝑙𝑙𝑙𝑙10 [𝐵𝐵])𝐶𝐶

where 𝑌𝑌 is the % cell viability, 𝐷𝐷 is a minimum value for the cell viability, 𝐴𝐴 is a maximum

value for the cell viability, 𝐵𝐵 is the IC50 concentration (µM), 𝐶𝐶 is the slope at the midpoint, and 𝑥𝑥

is the Dox concentration (µM). The four parameters 𝐴𝐴, 𝐵𝐵, 𝐶𝐶, and 𝐷𝐷 were optimized using a least

squares regression, and the values are given in Table 2. KB-3-1 and KB-V1 cells have a Dox IC50
of 1.3 µM and 184.0 µM, respectively, which shows that the KB-V1 cells are 147 times more
resistant (ratio of B-parameters) to a 2-hour treatment of free Dox treatment than are KB-3-1
cells.

Table 2. Parameters for the four parameter logistic equation to determine the IC50 of KB cells.
KB-V1 cell line
KB-3-1 cell line

A
0.9164
0.9867

B (IC50 µM)
184.0
1.250
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C
1.009
0.9888

D
0.0008
0.0000

As seen in Figure 13, there is a sharp decrease in cell viability for KB-3-1 cells between 1
(59%) and 10 µM (9%), whereas there is no statistical difference for the KB-V1 cells between 1
(81%) and 10 µM (86%). Therefore, Dox concentrations in the range of 5-10 µM were chosen
for further experiments to provide an optimal sensitivity to examine if folated eLipoDox can
reduce the viability of resistant KB-V1 cells to match that of sensitive KB-3-1 cells, thus
effectively reversing (or overcoming) the multidrug resistance of KB-V1 cells.

7.2.3

Characterization of Folated eLipoDox
eLiposomes were synthesized using the method described in Section 4.2.3. The technique

was slightly modified from published procedures [66] to formulate eLiposomes containing larger
emulsion droplets. Larger droplets have a lower Laplace pressure and may require less peak
negative pressure in order for ultrasound to provide optimal conditions for vaporization [121].
eLiposomes were made with or without targeting folate ligands on the surface. The zeta potential
of folate-targeted liposomes was -21.41 ± 1.85 mV (mean ± s.d.), whereas the zeta potential of
non-targeted liposomes was -9.48 ± 0.60 mV. The more negative zeta potential of folated
liposomes confirms the successful incorporation of DSPE-PEG-folate in the surface of the
targeted liposomes, as at neutral pH, the folic acid groups are ionized and negatively charged. A
pH gradient between the inside and outside of the eLiposome was established in order to
facilitate the remote loading of Dox inside of the eLiposomes. Synthesized eLipoDox had an
average diameter of 448 ± 16 nm (mean ± 95% c.i.) as determined by dynamic light scattering,
and was not statistically different (p=0.28) in size compared to folated eLipoDox, which had an
average diameter of 469 ± 36 nm.
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The concentration of Dox and eLipoDox was determined using UV/VIS
spectrophotometry. The peak absorbance at 480 nm was used with an extinction coefficient of
12,043 M-1 cm-1 as determined via a calibration curve of free Dox (Figure 14). For experiments
with eLipoDox, the target absorbance of Dox and eLipoDox was 0.50, which corresponds to a
Dox concentration of approximately 7 µM delivered to the cells.
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R² = 0.9955
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Figure 14. Calibration curve for the absorbance (480 nm) of free Dox in
PBS (pH 7.4) at room temperature (23°C).

7.2.4

Uptake of Folated and Non-folated eLipodox
The first set of experiments with eLipoDox was designed to see if eLipoDox particles had

been taken inside of KB-V1 cells by the time ultrasound would be applied. The liposomes were
tagged with a fluorescent label (DiI), and folate-targeted (Figure 15A,C) and non-targeted
(without folate, Figure 15B,D) eLipoDox were delivered to KB-V1 cells. After 2 hours, the cells
were rinsed with PBS and imaged using a confocal microscope (no US was applied). Any
fluorescence appearing in Figure 15C,D is the result of eLipoDox either attached to the surface
of the cell or inside of the cell. A sample slice from the stack of confocal images taken is shown
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Figure 15. Light (A) and confocal (C) images of KB-V1 cells exposed to folated
eLipoDox for 2 hours (no US). Light (B) and confocal (D) images of KB-V1 cells
exposed to eLipoDox for 2 hours (no US). (E) Average fluorescence intensity of
KB-V1 cells (n=6) from confocal images. Error bars represent 95% confidence
intervals.

in Figure 15A-D, corresponding to the slice with the highest fluorescence. The mean
fluorescence (Figure 15E) of KB-V1 cells exposed to folated eLipoDox was 300 times more than
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the mean fluorescence of cells exposed to eLipoDox (without folate). For the cells exposed to
folated eLipoDox, every cell appeared to emit fluorescence (Figure 15C); whereas when the cells
were exposed to eLipoDox without a targeting ligand, little to no fluorescence was observed
(Figure 15D). This suggests that folate promotes cytosolic uptake of liposomal doxorubicin to
KB-V1 cells.

7.2.5

Dox Release from eLipoDox
Previous studies [9, 121, 122] showed that calcein (a model drug) could be released from

eLiposomes upon insonation. Lattin et al. [122] synthesized 800-nm liposomes with PFC
emulsion droplets of two sizes (100 nm and 400 nm). They observed approximately 20% release
of calcein from PFC5 eLiposomes after 0.1s of 20-kHz US (1 W/cm2), and the release increased
with time (approx. 78% release after 5 s for 400 nm droplets, 40% release for 100-nm droplets).
They also looked at smaller (200 nm) liposomes with 100-nm droplets and observed less release
(approx. 12% release after 1s and 21% after 5s, 20 kHz, 1 W/cm2) compared to the larger
liposomes [121].
A similar study was performed in order to determine the release of doxorubicin from
eLiposomes. Dox is self-quenched at high concentrations [176]; therefore, the fluorescence of
Dox will increase as it is released from the liposome and diluted. The increase in the
fluorescence of Dox is proportional to the amount released. A QuantaMaster fluorometer
(Photon Technology International, Birmingham, NJ, USA) measured the fluorescence of Dox
released from folated eLipoDox and folated LipoDox (no emulsion droplet) after insonation
using excitation and emission wavelengths of 475 nm and 588 nm, respectively. The same
ultrasound conditions applied to cells in viability experiments (Section 7.2.6) were used in the
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release experiments (1 W/cm2, 20 kHz, 2 s total of US applied in 20 sec of 0.1-s pulses, 1:10
duty cycle). Figure 16 shows the raw data collected. A baseline fluorescence was first measured
and the fluorometer was paused, the cuvette was removed from the fluorometer, US was applied
to the cuvette, the cuvette was then replaced, and the fluorometer reading was continued. The
reading was paused after 50 seconds of measuring the fluorescence for another similar
application of US. After 2 rounds of insonation, SDS was added and gently mixed by repipetting
to release all of the encapsulated Dox from the liposomes and produce the fluorescence
corresponding to 100% release. The % 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 was calculated using the following equation:
% 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =

𝑓𝑓𝑈𝑈𝑈𝑈 −𝑓𝑓𝑖𝑖

𝑓𝑓𝑆𝑆𝑆𝑆𝑆𝑆 −𝑓𝑓𝑖𝑖

x100%

(7-2)

where 𝑓𝑓𝑖𝑖 is the initial (baseline) fluorescence, 𝑓𝑓𝑈𝑈𝑈𝑈 is the fluorescence after sonication, and 𝑓𝑓𝑆𝑆𝑆𝑆𝑆𝑆 is

the fluorescence after Dox release using SDS. Results shown in Figure 16 are very noisy because
of the low signal to noise ratio. Average release data are summarized in Table 3 and Figure 17.
Folated eLipoDox released an average of 78% of encapsulated Dox after 2 s of pulsed US,
whereas folated LipoDox only released 29% (Figure 17, Table 3, p=0.0002).
The presence of an emulsion droplet inside of the liposome caused a significant increase
in the release of Dox from liposomes. The majority of Dox was released from folated eLipoDox
after only 2 s of pulsed US. An additional 2 s of US did not produce any further significant
increase in Dox released from folated eLipoDox compared to the first 2 s of US (82% total
release to 78%, p=0.25); however, another 2 s of US did show significant increase in the release
of Dox from folated LipoDox (no emulsion droplet) (29% to 51%, p=0.02).
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Figure 16. Dox release from folated eLipoDox (black) and folated LipoDox (red) measured by
fluorescence. Pulsed US (1 W/cm2, 20 kHz, 2 s total of US applied in 20 sec of 0.1-s pulses, 1:10
duty cycle) was applied at 50 s and 100 s. SDS was added at 150 s.
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Figure 17. Average Dox release from folated eLipoDox (feLD, black/solid) and folated LipoDox (fLD,
red/hatched) measured by fluorescence. A baseline fluorescence (No US) was first measured. US was
then applied twice (1 W/cm2, 20 kHz, 2 s total of US applied in 20 sec of 0.1-s pulses, 1:10 duty cycle)
with the fluorescence measured after each insonation. Finally, SDS was added to achieve 100% release.
Error bars represent the 95% confidence interval. (n=3).
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Table 3. Average release of Dox from folated eLipoDox (feLD) and eLipoDox (eLD) after insonation (1
W/cm2, 20 kHz, 2 s total of US applied in 20 sec of 0.1-s pulses, 1:10 duty cycle).
feLD 1

feLD 2

feLD 3

fLD 1

fLD 2

fLD 3

feLD
Avg

fLD
Avg

p-value
(feLD v fLD)

US 1

76.3%

75.7%

80.9%

29.0%

35.1%

24.0%

77.5%

29.4%

0.0002

US 2

77.0%

82.1%

86.6%

44.7%

59.7%

49.6%

81.9%

51.3%

0.0042

Previous data by Javadi et al. [9] showed that the presence of both a targeting folate
ligand on the surface of the eLiposome and an emulsion droplet inside the liposome increased
the calcein fluorescence inside of HeLa cells after insonation. Our results show that folated
eLipoDox is taken inside of the cells after 2 hours (Figure 15C), and that, at this time, a 2-sec
pulse of US can cause the release of the bulk of encapsulated Dox from folated eLipoDox (Figure
17). These results suggest that US can be used to trigger an instantaneous release of Dox from

folated eLipoDox directly to the cell cytosol of MDR cells.

7.2.6

Cell Viability Experiments
We investigated the viability of KB cells after the delivery of folated eLipoDox and the

application of US. Folate-targeted and non-targeted eLipoDox, as well as folate- targeted
LipoDox (no emulsion droplet) were synthesized and diluted to approximately 7 µM in the cell
suspension. Both KB-V1 and KB-3-1 cells were incubated with either PBS, free Dox (7 µM),
folated eLiposomes (No Dox), folated LipoDox (no emulsion droplet), eLipoDox, or folated
eLipoDox for 2 hours before the samples were insonated in selected wells in a 24-well plate (1
W/cm2, 20 kHz, 2 s total of US applied in 20 sec of 0.1-s pulses, 1:10 duty cycle). After US was
applied to the selected wells, all of the cells were rinsed with 0.5 mL of PBS. The PBS was
removed and 0.9 mL of fresh growth media was added to the wells. An MTT cell viability assay
was performed 48 hours after insonation and the cell viability results are shown in Figure 18.
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Figure 18. Mean cell viability of KB-V1 (blue) and KB-3-1 (orange) cells measured by an MTT assay 48
hours after drug delivery. Concentration of Dox is approximately 7 uM. Cells were either treated with US
(hatched bars, 1 W/cm2, 20 kHz, 2 s total of US applied in 20 sec of 0.1-s pulses, 1:10 duty cycle) or
without US (solid bars). Error bars represent the 95% confidence interval. (n ≥ 3).

Absorbance at 560 nm was measured using a plate reader with the absorbance at 700 nm
subtracted. The percent viability for each condition is referenced to cells exposed to PBS but
without any insonation (PBS No US) for the given cell line (resistant or sensitive). At the
concentration of Dox used in these experiments (7 µM), the viability of MDR KB-V1 cells
exposed to free Dox is above 90% with or without ultrasound, suggesting that the resistant
cancer cells can quickly export any Dox that diffuses into the cell. KB-3-1 cells are unable to
export Dox as quickly due to the lack of P-gp pumps, compared to KB-V1 cells [177], as can be
seen from the lower viability (47%) in response to treatment with free Dox.
Figure 18 contains all data from many experiments. For clarity, I will discuss various

aspects, comparisons, and analyses of sub-sections of this data set in the subsequent sections.
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7.2.6.1 Cytotoxicity of folated eLiposomes
KB-V1 and KB-3-1 cells were both treated with folated eLiposomes without Dox to
determine the cytotoxicity of the drug delivery vehicle. During the synthesis of folated
eLipoDox, the folated eLiposomes were split into two separate vials before loading Dox into the
eLiposomes. Dox in PBS was added to one vial (folated eLipoDox), and to the other vial an
equal amount of PBS was added (folated eLiposomes without Dox). Folated eLiposomes were
then treated the same way as the folated eLipoDox. KB-V1 cells had a cell viability of 85%
(Figure 19) and KB-3-1 cells had a cell viability of 83% when treated with folated eLiposomes
(no Dox) without US (not statistically different). Cell viability slightly increased for both KB-V1
cells (90%) and KB-3-1 cells (94%) when US was applied, but the change was not statistically
significant. The viability of cells exposed to folated eLiposomes without Dox averaged less than
100%, but was not statistically different for any unloaded formulation.

140.0%
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120.0%

84.9%

90.4%

94.3%
83.3%

100.0%
80.0%
60.0%
40.0%
20.0%
0.0%

Folated eLiposomes
KB-V1 No US

KB-V1 US

KB-3-1 No US

KB-3-1 US

Figure 19. Cell viability of KB-V1 and KB-3-1 cells treated
with folated eLiposomes. Error bars represent 95%
confidence interval (n=10).

81

Other studies [119, 178] investigating the cytotoxicity of different cell lines treated with
Dox liposomes attached to PFC microbubbles similarly report 10-20% killing of cells treated
with just their constructs and US (no Dox). In this study, the killing of KB cells treated with
folated eLiposomes with or without US was not statistically significant compared to the PBS
only control (Figure 18). Thus, folated eLiposomes without drug have minimal effect on the cell
viability of KB cells.

7.2.6.2 Effect of ultrasound
Some cells were treated with PBS and US to verify that the US conditions did not have a
significant effect on the cell growth. The results show that there is no significant difference due
to the application of only US to KB-V1 (99%) or KB-3-1 (97%) cells (p>0.05 in both cases, see
Figure 20A).

Ultrasound did significantly increase the killing of KB-V1 cells treated with free Dox,
decreasing the viability from 97% to 90% (p=0.029, Figure 20B). This slight decrease in viability
could be attributed to the cell membrane becoming more permeable for a short time after
insonation, which is not unusual [179], thus increasing the influx of Dox. The cells were washed
within 20 minutes of US being applied, which would allow a short time for a small amount of
free Dox to more easily diffuse into the cell than normally would enter without insonation.
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Figure 20. Cell viability of KB-V1 and KB-3-1 cells treated with PBS (A), free Dox (B), folated LipoDox
(C) or folated eLipoDox (D). Error bars represent 95% confidence interval (n≥3).
Figure 17 showed that ultrasonic insonation can release approximately 29% of

encapsulated Dox from folated LipoDox (no emulsion droplet) and 78% from folated eLipoDox.
Although insonation produces 29% release of Dox from folated LipoDox with US in the absence
of cells, there is no significant difference due to insonation when folated LipoDox was used
against KB-V1 or KB-3-1 cells (Figure 20C). There is, however, a significant (p=0.047) decrease
in the cell viability observed after insonation of KB-V1 cells treated with folated eLipoDox
(Figure 20D). Yet, while statistically significant, the decrease in viability is not substantial (60%
to 53%). The reason for this relatively small decrease in viability is attributed to the instability of
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the folated eLipoDox once it has been endocytosed by the cell, and therefore produces low
viability of cells exposed to folated eLipoDox even when not insonated (60% for KB-V1 cells,
33% for KB-3-1 cells). This will be discussed later in Section 7.2.7. Surprisingly, ultrasound has
a negligible effect on the viability of KB cells for any of the conditions shown in Figure 18 and
Figure 20 which includes folated eLiposomes with and without Dox in the liposomes. While

ultrasound does not produce a pronounced difference, Dox produces a significant difference, as
does folate, which will be discussed next.

7.2.6.3 Effect of folate
As mentioned previously, folate induces much more uptake of eLipoDox. Figure 15
shows the uptake of folated eLipoDox compared to non-folated eLipoDox. The cells shown in
Figure 15 were rinsed with PBS prior to preparation for confocal microscopy, so only free Dox
inside of the cell or eLipoDox inside of or bound to the cell was present to create fluorescence in
the image. This result suggests that folated eLipoDox can release a significant amount of Dox to
the cytosol of the cell, whereas eLipoDox does not induce uptake by the cell, so there is a
negligible amount of Dox released directly to the cell cytosol. This is supported by the cell
viability data shown in Figure 21. KB-V1 cells have a viability of 84% when treated with
eLipoDox (Figure 21A), which is statistically higher when compared to cells treated with folated
eLipoDox (60%, p=0.003), but not statistically different when compared to cells treated with free
Dox (97%, p=0.076).
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Figure 21. Cell viability of resistant KB-V1(A) and sensitive KB-3-1 (B) cells treated with
Dox, eLipoDox, or folated eLipoDox. No Ultrasound was applied. Error bars represent 95%
confidence interval (n≥8).
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The importance of a folate ligand for cytosolic delivery of Dox is also observed by
comparing the viability of KB-3-1 (sensitive) cells treated with Dox, eLipoDox or folated
eLipoDox (Figure 21B). Non-folated eLipoDox kills significantly less KB-3-1 cells (62%) than
either free Dox (47%, p<0.01) or folated eLipoDox (33%, p<0.0001). It is unlikely that large
quantities of eLipoDox (without folate) are taken into the cell during the 2 hours of incubation
(see Figure 15D). Gabizon et al. report that PEGylated liposomal doxorubicin (no emulsion
droplet) passively accumulates in the tumor interstitial fluid and gradually releases doxorubicin
without any significant interaction with tumor cells [180]. Thus, Dox released from eLipoDox
(either by diffusional escape or by PFC5 droplet vaporization) will remain outside of the cell,
and the concentration of free Dox outside of the cell will be less than that of cells treated with
free Dox. Since, in our experiments, the media containing any drug is removed after 2 hours of
incubation with eLipoDox, and the cells are rinsed with PBS to reduce any residual drug, there is
minimal time for any Dox released from eLipoDox to diffuse into the cell. Attaching folate to
eLipoDox facilitates endocytosis by the cell (see Figure 15C); thus, Dox can be released directly
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from folated eLipoDox to the cell cytosol. Cell viability of KB-3-1 cells treated with folated
eLipoDox (33%, Figure 21B) is significantly less than the cell viability of Dox-treated KB-3-1
cells (47%, p<0.0001). These results support the hypothesis that folate greatly enhances the
cytosolic delivery of doxorubicin from eLipoDox.

7.2.6.4 Effect of emulsion droplet
As mentioned, KB cells were treated with folated LipoDox (no emulsion droplet) to
confirm that an emulsion droplet is necessary to get adequate release to the cytosol of the cells.
There is little to no killing of KB-V1 or KB-3-1 cells treated with folated LipoDox (see Figure
22); however, cell viability is significantly reduced (p<0.0001, No US) for both KB-V1 and KB-

3-1 cells when there is an emulsion droplet encapsulated inside the liposome (folated eLipoDox).
The presence of an emulsion droplet makes a statistically significant difference, with or without
ultrasound.
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Figure 22. Cell viability of resistant KB-V1(A) and sensitive KB-3-1 (B) cells treated with folated
LipoDox or folated eLipoDox. Error bars represent 95% confidence interval (n≥3).
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The presence of an emulsion droplet inside of folated eLipoDox apparently provides a
possible mechanism for the release of Dox from the liposome directly to the cell cytosol. The
PFC5 droplet (100-200 nm) will expand 5 times in diameter (500-1000 nm) when it vaporizes,
thus rupturing the liposome and most likely the endosome as well, as endosomes are less than 1
µm in size [181]. This will provide a greater opportunity for Dox molecules to reach the nucleus
and initiate apoptosis. Interestingly, ultrasound does not appear to be necessary to provide a
significant amount of killing of KB-V1 or KB-3-1 cells with folated eLipoDox, and insonation
provides only a marginal increase in killing KB-V1 cells (Figure 22).

7.2.7

Instability of Endocytosed Folated eLipoDox
As mentioned in Section 7.2.6.2 one possibility for the significant amount of killing when

cells were incubated with folated eLipoDox (in the absence of US) is that the folated eLipoDox
is not stable once it is endocytosed by the cell. In order for US to trigger the release of
doxorubicin from eLipoDox to deliver it to the cell cytosol, the eLipoDox construct must be
endocytosed and the PFC5 droplet must vaporize when, and only when, US is applied. One
hypothesis as to why there is significant killing when KB cells are treated with folated eLipoDox
(but without insonation) follows: the folated eLipoDox is endocytosed by the cell; however, the
PFC5 droplet vaporizes whether or not US is applied. This hypothesis is consistent with all the
data, but is difficult to prove.
Our proposed mechanism underlying this hypothesis is that the Dox precipitates with
sulfate to form fibrous crystals during the process of loading doxorubicin. These solid fibers
provide nucleation sites for the PFC5 molecules inside of the liposome to nucleate to a gas
bubble, independent of the application of US. When folated eLipoDox enters the cell through
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folate-mediated endocytosis, the PFC gas bubble forms spontaneously, releasing Dox to the cell
cytosol without application of ultrasound. Confocal images (see Figure 15) show that folated
eLipoDox is taken into the cell, whereas eLipoDox (no folate) has minimal uptake into the cell.
This observation along with the increased killing of KB-V1 and KB-3-1 cells (see Figure 18)
treated with folated eLipoDox compared to either folated eLiposomes (no Dox) or eLipoDox (no
folate, Dox released external to the cell) suggests that the Dox is released from the folated
eLipoDox after endocytosis, and not before. The environment within the endosome is
significantly different from the environment surrounding the cell. The endosome has proton
pumps to lower the pH and regulate the osmotic pressure [182]. It also has various enzymes to
degrade encapsulated cargo [6]. Early endosomes can also have a smaller diameter (~250 nm)
than the liposome (~450 nm) [181], which would compress the liposomal bilayer and increase
the contact between the Dox fiber and PFC5 droplet. While we do not postulate what it is about
the new environment within the endosome that causes the release of Dox from eLiposomes, we
do postulate that the release is caused from the vaporization of the PFC5 droplet. The
observation that an emulsion droplet within the liposome is necessary to achieve significant
killing of KB-V1 or KB-3-1 cells (see Figure 22) suggests that vaporization is likely the cause of
Dox release from the eLiposome once the construct has been endocytosed. The hypothesis that
the Dox fibers provide nucleation sites for the PFC5 droplet inside of the folated eLipoDox was
explored and tested by gleaning results from literature and from some additional quantitative and
qualitative experiments.
The formation of fibrous crystals of Dox sulfate when using an ammonium sulfate pH
gradient has been reported by many groups [183]. But there are also other reports that Dox fibers
form when liposomes are loaded using a citrate pH gradient [129, 184] and a magnesium sulfate
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pH gradient [130]. These studies show that the precipitated Dox salts will form bundles of fibers
as the drug to lipid (D/L) mass ratio increases, with simple rod-like fibers forming at least by a
D/L ratio of 0.05 (see Figure 23). As the D/L ratio increases further, the fibers become thicker
and appear to take up more volume inside the liposomes, with some shapes of the Dox crystals
appearing to be circular or triangular and even globular at higher (D/L) ratios [129, 130]. As can
be seen in Figure 23, the Dox fibers can distort the spherical shape of the liposomes, which would
introduce significant stress on the liposomal membrane.
Both Johnston et al. and Li et al. noted that the percentage of encapsulated Dox
eventually released from liposomes decreased as the D/L ratio increased [129, 130]. Additionally,
Li et al. showed that the significant increase in retention of Dox inside of the liposomes
corresponds to the Dox fibers forming bundles of fibers [129]. We postulated that these Dox
fibers (Figure 23) provide heterogeneous nucleation sites for the initiation of the PFC5 gas phase,
and that the liquid droplet will provide PFC5 molecules to form a gas phase, whether or not US
is applied. For our experiments, the initial D/L ratio was 0.005, assuming no lipids were lost
during the synthesis procedure. It should be noted that some lipids were lost during the pillow
density separation (process that separates empty liposomes from eLiposomes and emulsion
droplets), although the exact amount of loss was not quantified.
To test this nucleation hypothesis, experiments were performed with folated eLipoDox to
determine the effect of the initial drug to lipid ratio. Folated eLiposomes were synthesized and
split into multiple vials, with each vial having the same lipid concentration. Various
concentrations of Dox in PBS, but equal volumes, were then added to the multiple vials. At the
highest concentration of Dox (2 mg/mL) used in these experiments the initial D/L ratio was 0.16,
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assuming no lipids were lost. But even in the most dubious case of losing 90% of lipids, the ratio
would be even higher, sufficiently high to form fibrous crystals.

Figure 23. Cryo-transmission electron microscopy of DSPC/Chol
(55/45 mol%) liposomes containing doxorubicin at different drug-tolipid ratios. Panels represent empty liposomes (A) and D/L ratios
(wt/wt) of 0.05 (B), 0.18 (C), 0.37 (D), and 0.46 (E). The bar in panels
A to E represents 200 nm in all micrographs and all micrographs (A–E)
are shown at the same magnification. Each panel is a representative
image from at least 20 images per D/L ratio. Figure used by permission
from [130].
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We expected that due to the presence of a PFC5 emulsion droplet in the liposome, there
would be a maximum amount of loading possible before the emulsion droplet would be crowded
into touching the Dox fibers and form vapor even before delivering eLipoDox to the cells. Thus,
eLipoDox loaded at high D/L ratios were expected to be the most unstable and therefore the most
likely for the PFC5 emulsion droplet to vaporize inside of the liposome (due to less space inside
of the liposome for the emulsion droplet). We expected eLipoDox at lower D/L ratios to be more
stable and have higher cell viability when not insonated. When the D/L ratio is too low, few if
any Dox crystals would form and molecular Dox would be more likely to permeate out [129]
before the folated eLipoDox could be endocytosed; thus we expected the cell viability to also be
higher (especially for KB-V1 cells) because the Dox would escape before endocytosis and would
need to diffuse across the cell membrane into the cell, which is less likely to reduce cell viability.
Several experiments were performed with Dox loading concentrations between 0.05-2
mg/mL, corresponding to D/L ratios between 0.004-0.16 (assuming no lipids were lost during
synthesis). The D/L ratios would increase if lipids were lost during synthesis (i.e. if 50% lipids
are lost, then D/L ratios would be between 0.008-0.32). We were not able to make and measure a
D/L ratio lower than 0.001 due to limitations in detector sensitivity.
Figure 24 shows that except for the peak at the Dox loading of 0.25 mg/mL (-0.6 on a log

basis), there was no significant and meaningful difference due to the D/L ratio in cell viability of
KB-3-1 or KB-V1 cells. Furthermore, there was no significant difference in viability between
cells with and without insonation (data not shown) for the D/L ratios investigated. These results
suggest that even a low concentration of Dox loading is sufficient to provide a possible
nucleation site for PFC5 emulsions also loaded inside the liposome.
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Figure 24. Cell viability of KB cells treated with folated eLipoDox with different initial drug to lipid
ratios. The x-axis refers to the logarithm of the initial Dox concentration (mg/mL) added to an equal
volume of folated eLiposomes. If no lipids were lost during the synthesis of folated eLiposomes, the
largest D/L ratio would be 0.16. Error bars refer to the 95% confidence interval (n≥4).

Further support of the heterogeneous nucleation of gas was provided by doing
experiments in which Dox fibers were not formed. Li et al. [129] showed that Dox fibers are not
formed when Dox is loaded using a monoanionic buffer (such as glutamate). We performed
qualitative experiments comparing the presence of gas bubbles when Dox was loaded into
folated Liposomes containing a PFC5 emulsion droplet using glutamate pH gradients versus
ammonium sulfate pH gradients. Our hypothesis suggests that there would be the nucleation of
bubbles when ammonium sulfate is used as the pH gradient due to the presence of a Dox fiber
inside the eLiposome. Minimal bubbles will be observed, if any, when glutamate is used because
no Dox fibers are formed during the loading process and no Dox fibers would be present to
nucleate the PFC5 liquid droplets to gas.
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Dox was loaded into folated eLiposomes using an ammonium sulfate pH gradient or a
potassium glutamate pH gradient. An equal volume of Dox in PBS (2 mg/mL) and folated
eLiposomes were added together and allowed to incubate in the refrigerator (4°C) overnight for
17 hours. The next morning (at 17 hours) bubbles were observed in the vial containing folated
eLipoDox formed using an ammonium sulfate pH gradient, but no bubbles were observed in the
vial containing folated eLipoDox formed using a potassium glutamate pH gradient (Figure 25A).
The vials were then kept at room temperature (23°C) for 90 additional minutes (Figure 25B)
after which we observed more (and larger) bubbles for the ammonium sulfate loaded eLipoDox
sample. There were also a few small bubbles that did appear in the vial with folated eLipoDox
loaded using a glutamate pH gradient. Loading of Dox in folated eLiposomes for experiments in
Section 7.2.6 used an ammonium sulfate pH gradient at 4°C and 18 hrs, and a Dox concentration
of 0.1 mg/mL; yet no bubbles were observed. The presence of a significant amount of bubbles
when loading 2 mg/mL in the ammonium sulfate folated eLipoDox but not in the glutamate
folated eLipoDox (Figure 25) supports our postulate that the presence of a Dox fiber provides a
nucleation site to form perfluoropentane gas bubbles.

A)
B)
Figure 25. Folated eLipoDox after synthesis and incubation with Dox (2mg/mL). Right vial in (A) and
(B) is Dox loading with potassium glutamate. Left vial in (A) and (B) is Dox loading with ammonium
sulfate. (A) Immediately after loading Dox for 17 hours at 4°C. (B) After 90 additional minutes sitting
at room temperature (23°C).
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Li et al. [129] report that when glutamate is used as the pH gradient, Dox is could not be
loaded to as high of a Dox concentration inside of the liposome because Dox does not form
fibrous crystals. They also report that at the maximum loading of Dox inside glutamate
liposomes, 60% of the Dox is released within 30 minutes in 50% human plasma. In comparison,
Dox that formed fibrous bundles with citrate released less than 10% of Dox after 30 minutes in
50% human plasma. Thus while loading folated eLipoDox using a glutamate gradient is a
possibility, we did not perform any cell viability experiments with glutamate eLipoDox because
the resulting construct would not be useful in a clinical application.

7.3

Summary and Conclusion
Dox-sensitive KB-3-1 cells and Dox-resistant KB-V1 cells were used to investigate the

effectiveness of cytosolic delivery of Dox to overcome multidrug resistance. The folated
eLiposomes (no Dox) used in this study had minimal effect on the growth of KB cells (10-20%
killing) and viability was not statistically different from the negative control of PBS without
insonation. Folated eLipoDox was shown to be inside of the cell after 2 hours of incubation,
whereas there was no observable uptake of non-folated (non-targeted) eLipoDox after 2 hours.
Release of the drug inside the cell, as is the case with folated eLipoDox, significantly increased
the killing of sensitive KB-3-1 (47% to 33%) cells and resistant KB-V1 (97% to 60%) cells
compared to cells treated with free Dox. Non-targeted eLipoDox actually killed KB-3-1 cells less
than free Dox (62% v 47%) presumably because the construct is still outside of the cells when
the Dox is released, and the lower concentration of external free Dox resulted in a lower driving
force for Dox to diffuse into the cell.
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Ultrasound at mild conditions (1 W/cm2, 20 kHz, 2 s total of US applied in 20 sec of 0.1-s
pulses, 1:10 duty cycle) can release approximately 78% of encapsulated Dox inside of folated
eLipoDox in vitro. Despite folated eLipoDox being endocytosed by cells and US being able to
release Dox, there was no substantial difference in cell viability of KB-3-1 or KB-V1 cells due to
the application of US on cells treated with folated eLipoDox.
Our current hypothesis as to why insonation produces no significant difference in KB cell
viability when treated with folated eLipoDox is that the emulsion droplet vaporizes once
endocytosed by the cells, even without US. This hypothesis is difficult to prove, but is supported
by the presence of bubbles in vials containing folated eLipoDox loaded using an ammonium
sulfate buffer, but not with a potassium glutamate buffer. The Dox purportedly forms a
heterogeneous phase of fibers inside of the liposomes only when loaded using a multianionic
buffer. It is our hypothesis that the Dox fiber provides a nucleation site for PFC5 to form a gas
phase that ruptures the liposome and causes the release of Dox without the application of US.
While US did not make a substantial difference in killing cells treated with folated
eLipoDox, a higher percentage of KB cells were killed when treated with folated eLipoDox
compared to an equivalent concentration of free Dox. Cell viability assays also show that the
most cytotoxicity is produced by a combination of folate attached to the liposome, an emulsion
droplet inside of the liposome, and Dox loaded in the liposome. Cytosolic delivery of Dox via
folated eLipoDox did enhance the killing of MDR cells, reducing the viability to 60%, compared
to 97% for MDR cells treated with free Dox. However, it did not fully overcome the multidrug
resistance of MDR KB-V1 cells at the administered Dox concentration (7 µM).
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8

8.1

CO-DELIVERY OF FOLATED ELIPODOX AND VERAPAMIL

Introduction
In the previous chapter, we investigated the effectiveness of folate-targeted doxorubicin-

loaded eLiposomes (folated eLipoDox) at overcoming the resistance of KB-V1 cells to
doxorubicin (Dox). Experiments were conducted at concentrations of Dox that killed a negligible
amount of Dox-resistant KB-V1 cells and more than 50% of Dox-sensitive KB-3-1 cells when
treated with free Dox (not encapsulated inside of a liposome). Results showed that folated
eLipoDox reduced the viability of KB-V1 and KB-3-1 cells; however, the viability of KB-V1
cells was still higher than the viability of KB-3-1 cells treated with either free Dox or folated
eLipoDox. We concluded that the cytosolic delivery of folated eLipoDox at this concentration is
not sufficient to overcome the resistance of KB-V1 cells to Dox.
These KB-V1 cells acquired a resistance to Dox through exposure to increasing
concentrations of vinblastine [138]. This phenomenon of acquiring resistance to drugs other than
the sensitizing drug is known as multidrug resistance. KB-V1 cells are multidrug resistant
because they express an increased number of active efflux pumps in the cell membrane of the
cancer cells and can therefore export Dox at a much faster rate than cancer cells or other cells
with normal expression levels of efflux pumps. It is our hypothesis that inhibiting the function of
the efflux pumps would increase the effectiveness of cytosolic delivery of Dox via folated
eLipoDox and thus overcome the multidrug resistance of KB-V1 cells.
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Co-delivery of Dox with an inhibitor is not a new concept and many researchers have
observed a synergistic enhancement of killing multidrug-resistant (MDR) cells through the codelivery of verapamil and Dox [185-188]. Verapamil (Vrp) is a first generation inhibitor that was
used in the experiments presented in this chapter. As a calcium channel blocker, it inhibits the
function of the efflux pumps and reduces the ability of the cells to export unwanted materials
from the cytosol, thereby giving Dox a longer opportunity to reach the nucleus and initiate
apoptosis. The objective of the studies in this chapter is to determine if co-delivering verapamil
with folated eLipoDox will enhance the killing of KB-V1 cells compared to folated eLipoDox
alone and be able to kill KB-V1 cells with the same effectiveness as the non-resistant KB-3-1
cells.

8.2
8.2.1

Results
Optimal Concentration of Free Verapamil to Deliver with Free Doxorubicin
Doxorubicin and verapamil have a synergistic relationship in regards to killing resistant

cancer cells, depending on the concentration of Dox and verapamil delivered. The first sets of
experiments were conducted to determine the toxicity of free verapamil toward KB cells and to
find an optimal concentration of verapamil to use in combination with Dox. Various
concentrations (0.003-3 mg/mL) of 0.1 mL of free (soluble) verapamil were delivered to KB-V1
and KB-3-1 cells in 24-well plates. The final concentration of verapamil was between 0.5 and
500 µM. Verapamil was incubated (37°C, 5% CO2) with the cells for 2 hours before the media
was removed, the cells were rinsed with 0.5 mL of PBS, and 0.9 mL of fresh media was added to
the cells. An MTT assay was performed 48 hours later to determine cell viability. As seen in
Figure 26, KB-V1 and KB-3-1 cells had a viability of 87% and 93%, respectively, when treated

with the maximum concentration (500 µM) of verapamil. These viabilities were not statistically
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different (p=0.62). By itself, verapamil did not produce a significant amount of toxicity at the
concentrations and the conditions for these experiments.
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Figure 26. Mean cell viability of resistant KB-V1 and sensitive KB-3-1 cells measured by
an MTT assay 48 hours after drug delivery. Cells were treated with 0.1 mL of free
verapamil (0.003-3 mg/mL). Final concentration of verapamil was between 0.5-500 µM.
Error bars represent the 95% confidence interval (n=3).

The optimal concentration of Dox needed to observe the synergistic effects of the codelivery of Dox and verapamil (Dox+Vrp) would be one in which Dox-treated KB-V1 cells are
very viable while the Dox-treated KB-3-1 cells are not. This would allow the KB-V1 cells to
have a range of viability that would show sensitivity. As seen in Figure 27 the optimal Dox
concentration for this experiment is about 50 µM (1.7 on a log scale, red circles) as Dox killed
the majority of KB-3-1 cells, but KB-V1 cells were still very viable (76%).
Various concentrations of verapamil (0.5-500 µM) were co-delivered with free Dox (50
µM) to KB-V1 cells (Figure 28). The objective of these experiments was to determine the
optimal verapamil concentration that produces a synergistic enhancement of killing KB-V1 cells
when co-delivered with Dox. As seen from Figure 28, the synergistic toxicity of the co-delivery
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of Dox+Vrp increased as the concentration of verapamil increased, and the effect did not appear
to taper off at the maximum delivered concentration of verapamil (500 µM). KB-V1 cells had a
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Figure 27. Dose response curve for KB-3-1 and KB-V1 cells treated with Dox. Red
circles indicate the optimal Dox concentration to observe the sensitivity of verapamil
when co-delivered with Dox. Error bars represent the standard deviation of experimental
data points (n=3).

viability of 77% (Figure 28) when treated with 50 µM free Dox and a viability of 87% (Figure 26)
when treated with 500 µM free verapamil. The viability of KB-V1 cells dropped to 39% (Figure
28) when Dox (50 µM ) + Vrp (500 µM) were delivered together. If the toxicity of co-delivered

Dox+Vrp were only additive functions of the toxicity of free Dox and free verapamil, the
viability of Dox+Vrp-treated KB-V1 cells should be about 64%; however, the viability is much
lower (39%), showing that Dox and verapamil have a synergistic toxicity towards KB-V1 cells at
certain drug concentrations. While the viability of Dox+Verap-treated KB-V1 cells (39%, Figure
28) was significantly (p=0.005) less than Dox-treated KB-V1 cells (77%), Dox-treated KB-3-1

cells still had a significantly lower viability (6.4%, p<0.0001). The experiments reported in the
following section (8.2.2) investigated the enhanced toxicity of Dox+Vrp when Dox was
delivered directly to the cytosol via folated eLipoDox.
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Figure 28. Mean cell viability of KB-V1 and KB-3-1 cells measured by an MTT assay 48 hours
after drug delivery. Cells were treated with Dox (50 µM) or Dox(50 µM )+Vrp(0.5-500 µM).
Error bars represent the 95% confidence interval (n=3).

There is a minimum concentration of verapamil needed to produce a synergistic effect in
the co-delivery of Dox+Vrp. The cell viability of Dox+Vrp treated KB-V1 cells at verapamil
concentrations ≤ 5 µM were not significantly different from Dox-treated KB-V1 cells. However,
at some verapamil concentration between 5 and 50 µM the co-delivery of Dox+Vrp produced the
desired synergistic effect. Since the viability of KB-V1 and KB-3-1 cells treated with 500 µM
free verapamil (Figure 26) was still relatively high and this concentration had the greatest
synergistic effect when co-delivered with Dox (Figure 28), all subsequent co-delivery
experiments used 500 µM verapamil.

8.2.2 Cell Viability for Co-delivery Experiments
KB-V1 and KB-3-1 cells were treated with free Dox, free verapamil, free Dox+Vrp,
folated eLipoDox, and folated eLipoDox plus verapamil (feLD+Vrp). Dox and synthesized
folated eLipoDox were diluted to absorbance values of approximately 0.5 (which corresponded
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to a final concentration of approximately 6.5 µM delivered to the cells). Cells were incubated
with the drug(s) or control for 2 hours before US was applied. After US, the cells were rinsed
with 0.5 mL of PBS, the PBS was removed, and 0.9 mL of fresh media was added to the cells.
An MTT assay was performed 48 hours after administering the drugs to the cells. Absorbance at
560 nm was measured using a plate reader with the absorbance at 700 nm subtracted. The
percent viability for each condition has a reference to cells exposed to PBS but not US (PBS No
US) for the given cell line, and the cell viability results are shown in Figure 29. Various aspects,
comparisons, and analyses of subsections of these data are discussed in the subsequent sections.
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Figure 29. Mean cell viability of resistant KB-V1 (blue) and sensitive KB-3-1 (orange) cells
measured by an MTT assay 48 hours after drug delivery. Concentration of Dox and verapamil was
approximately 6.5 µM and 500 µM, respectively. Cells were either treated with US (hatched bars, 1
W/cm2, 20 kHz, 2 s total of US applied in 20 sec of 0.1-s pulses, 1:10 duty cycle) or without US
(solid bars). Error bars represent the 95% confidence interval. (n ≥ 4).

8.2.2.1 Effects of Ultrasound
Chapter 7 presented and discussed reasons why ultrasound was not effective at
controlling the release of doxorubicin from folated eLipoDox. It was our hypothesis, considering
the results in Chapter 7, that US would not have a significant additional effect on the killing of

101

KB cells treated with a co-delivery of folated eLipoDox and verapamil (feLd+Vrp). As can be
seen in Figure 30A, there was no significant difference due to US for KB cells treated with
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A)
B)
Figure 30. Cell viability of KB-V1 and KB-3-1 cells treated with folated eLipoDox plus verapamil (A) or
free Dox plus verapamil (B). Error bars represent the 95% confidence interval (n≥4).

The cell viability of Dox+Vrp-treated KB-3-1cells did decrease from 47% to 29% when
US was applied (Figure 30B); however, the change was not significant (p=0.07). There were no
conditions for any of the experiments presented in Figure 29 where US significantly enhanced
the killing of KB-cells. Section 7.2.6.2 discussed reasons why US had a negligible effect on the
viability of KB cells treated with free drug or folated eLipoDox, and it is believed these same
reasons apply when free Vrp is present.

8.2.2.2 Co-delivery of Free Dox and Free Verapamil
KB-V1 and KB-3-1 cells treated with 500 µM of free verapamil (Figure 31) had a cell
viability of 81% and 85%, respectively. The concentration of Dox delivered to the KB cells was
6.5 µM, slightly less than the concentration of Dox (7.0 µM) delivered to KB cells in Chapter 7.

102

As shown in Figure 31, KB-V1 cells treated with 6.5 µM Dox have a viability of 99% whereas
KB-3-1 cells have a cell viability of 46%. If the toxicity of Dox+Vrp were only additive
functions of the toxicity of free Dox and free verapamil, KB-V1 and KB-3-1 cells would have an
approximate cell viability of 80% and 31%, respectively. We observed (Figure 31), however, that
compared to Dox-treated KB cells, the co-delivery of Dox+Vrp had a synergistic enhancement in
killing resistant KB-V1 cells (50% v 99%, p=0.004) while making no difference in the killing of
sensitive KB-3-1 cells (47% v 46%, p=0.89). More importantly, however, there was no statistical
difference between the viability of KB-V1 and KB-3-1 cells treated with free Dox+Vrp (50 v
47%, p=0.74). At this concentration of Dox and Vrp, the multidrug resistance of KB-V1 cells to
the treatment of Dox was overcome with the co-delivery of verapamil (Dox+Vrp, Figure 31).
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Figure 31. Cell viability of KB-V1 and KB-3-1 cells treated with Dox (6.5 µM), verapamil
(500 µM), and Dox+Vrp (6.5 µM+500µM). No ultrasound was applied. Error bars represent
95% confidence interval (n≥4).

Verapamil is a calcium channel blocker, and will inhibit the function of the export pumps
of KB-V1 cells, thus decreasing the rate at which Dox is removed from the cytosol of the cells.
Perez-Soler et al. [16] measured the accumulation of Dox in KB (Dox-sensitive) and KB-V1
cells after 1 hour incubation with Dox (10 µg/mL) or Dox +Vrp (10 µg/mL each). Compared to
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cells treated with Dox alone, KB-V1 cells treated with Dox+Vrp increased the accumulation of
Dox by a factor of 2, but Dox+Vrp had no effect on the accumulation of Dox in sensitive KB
cells. Perez-Soler et al. [16] also looked at the retention of Dox in KB-V1 and KB cells. After a
1-hour incubation with Dox or Dox+Vrp, the cells were washed and cellular Dox retention was
measured 1 hour thereafter. Verapamil had no effect on the retention of Dox in sensitive KB
cells, but increased the retention of Dox by a factor of 2 for KB-V1 cells. The decreased cell
viability of Dox+Vrp-treated KB-V1 cells compared to Dox alone (Figure 31) can be attributed to
the increased accumulation and retention of Dox in the cytosol of the cell, which would grant
Dox molecules a longer time to accumulate in the nucleus and initiate apoptosis.
In sensitive cells, we observed no decrease in the viability of Dox+Vrp-treated KB-3-1
cells compared to KB-3-1 cells treated with Dox alone (Figure 31). Perez-Soler et al. [16]
observed no increase in the accumulation or retention of Dox in Dox-sensitive KB cells.
Therefore, verapamil had a negligible effect on the efflux of Dox molecules from the cytosol of
Dox-sensitive KB cells. Furthermore, we can infer that the accumulation, and therefore
cytotoxicity, of Dox in sensitive KB-3-1 cells was limited by the influx of Dox molecules to the
cytosol and not the export of Dox molecules from the cell. The viability of KB-3-1 cells can still
be reduced with a higher concentration of external Dox (Figure 27). Higher concentrations
outside of the cell would increase the concentration gradient between the inside and outside of
the cell, thus providing a greater driving force for diffusion of Dox into the cell and a higher
accumulation of Dox in the cytosol. While Dox+Vrp does not increase the killing of Doxsensitive KB cells, co-delivery of Dox+Vrp is as cytotoxic to Dox-resistant KB-V1 cells as to
Dox-sensitive KB cells.
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8.2.2.3 Co-delivery of Folated eLipoDox and Verapamil
While the co-delivery of free Dox+Vrp was shown to overcome the resistance of KB-V1
cells to Dox (Figure 31), it is not an optimal form of drug delivery because of the negative side
effects associated with the systemic delivery of non-encapsulated drugs. Encapsulation of Dox in
liposomes will help to reduce the cardiotoxicity and other negative side effects associated with
the systemic delivery of free Dox. As seen in Figure 29, folated eLipoDox was better at killing
the MDR KB-V1 cells than free Dox; however, it did not overcome the Dox resistance and kill
the KB-V1 cells as well as Dox alone killed the KB-3-1 cells. It was our hypothesis that the codelivery of folated eLipoDox and Verapamil would overcome the resistance of KB-V1 cells to
Dox and be more cytotoxic to KB cells than free Dox or free Dox+Vrp.
Figure 32 shows the cell viability of KB-V1 and KB-3-1 cells when treated with free

Dox+Vrp, folated eLipoDox, and feLD+Vrp. The viability of KB-V1 cells treated with free
Dox+Vrp was lower, but not statistically different, than the cell viability of KB-V1 cells treated
with folated eLipoDox (50 v 65%, p=0.10). Folated eLipoDox-treated KB-3-1 cells, interestingly,
had a lower cell viability than Dox+Vrp-treated KB-3-1 cells (47 v 35%); however the difference
was also not significant (p=0.08, Figure 32). We can therefore infer that delivering Dox directly
to the cell cytosol was as effective at killing KB cells as delivering free Dox and inhibiting the
export pumps with verapamil.
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Figure 32. Cell viability of resistant KB-V1 and sensitive KB-3-1 cells treated with Dox (6.5 µM)
plus verapamil (500 µM), folated eLipoDox (6.5 µM), and folated eLipoDox (6.5 µM) plus
verapamil (500 µM). No ultrasound was applied. Error bars represent 95% confidence interval
(n≥4).

The co-delivery of feLD+Vrp significantly reduced the viability of KB-V1 cells
compared to both folated eLipoDox alone (25 v 65%, p<0.0001) and Dox+Vrp (25 v 50%,
p=0.047; Figure 32). While the cell viability of feLD+Vrp-treated KB-3-1 did not significantly
decrease compared to feLD-treated KB-3-1 cells (29 v 35%, p=0.08), the cell viability did
significantly decrease compared to Dox+Vrp treated KB-3-1 cells (29 v 47%, p=0.0007, Figure
32). KB-V1 and KB-3-1 cells treated with feLD+Vrp had the lowest viability of any of the

experimental conditions (Figure 29). More importantly, KB-V1 cells were killed as effectively as
KB-3-1 cells when treated with feLD+Vrp (25 v 29%, p=0.38), supporting our hypothesis that
multidrug resistance can be overcome through inhibiting the efflux pumps as cancer drugs are
delivered directly to the cell cytosol.

8.3

Summary
The objective of the research presented in this chapter was to determine if the co-delivery

of verapamil with folated eLipoDox would be able to overcome the resistance of KB-V1 cells to
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Dox and kill KB-V1 cells as effectively as the sensitive KB-3-1 cells. Verapamil was shown to
have minimal toxicity to KB cells at verapamil concentrations up to 500 µM, and the co-delivery
of Dox (50 µM) with verapamil (500 µM) showed a significant synergistic toxicity to KB-V1
cells.
Further experiments showed that the co-delivery of Dox+Vrp was able to overcome the
resistance of KB-V1 cells to Dox. However, there was no enhanced killing of KB-3-1 cells
treated with Dox+Vrp. KB-V1 and KB-3-1 cells both saw a decrease in viability when treated
with feLD+Vrp, and, most importantly, there was no significant difference in their viability. As
observed in the results from Chapter 7, there was no significant difference in cell viability due to
the application of US for any of the experimental conditions presented in this chapter. We
conclude that the cytosolic delivery of Dox via folated eLipoDox combined with the blocking of
export pumps via verapamil can overcome the multidrug resistance of KB-V1 cells and even
significantly reduce the viability of Dox-sensitive KB-3-1 cells.
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9

9.1

CONCLUSIONS AND RECOMMENDATIONS

Summary and Conclusions
The overall objective of the presented research was to investigate the controlled release of

therapeutics directly to the cytosol of cancer cells in order to overcome multidrug resistance.
Cytosolic delivery of cancer drugs was hypothesized to be more effective at killing resistant
cancer cells than delivery of the drug outside of the cell. Producing drug release to the cytosol
would not only increase the amount of drug inside the cell, but also minimize the negative side
effects associated with a systemic (whole body) delivery of unencapsulated drugs. The results
from this research suggest that cytosolic delivery via a folated eLiposomes was more effective at
killing MDR cells and can be enhanced when co-delivered with an inhibitor to block the
functions of the export pumps.
The first set of experiments investigated whether eLiposomes were stable at body
temperature (37 °C) Results showed that a model drug (calcein) had minimal release at body
temperature; however, the release significantly increased as the temperature increased above
body temperature. The stability of the PFC5 emulsion droplets at body temperature (above
PFC5’s normal boiling point of 29 °C) is presumed to be the result of a high energy barrier for
nucleation after the formation of phospholipid stabilized emulsions. Release at higher
temperature was most likely the result of heterogeneous nucleation.
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Vaporization of PFC5 emulsion droplets at body temperature was first attempted with
laser-induced GNR heating. Problems with consistency in transferring GNRs from an aqueous
solution to PFC5, and the further investigation of the required power to vaporize the emulsion
droplets prompted a change from temperature induced vaporization of PFC5 droplets to a
pressure-induced vaporization. While studies do show that it is possible to vaporize PFC5
droplets with laser-induced GNR heating, the power required is not feasible in a safe, portable
device.
A Dox-sensitive and Dox-resistant strain of KB cells were used to investigate the
cytotoxicity of folate-targeted dox loaded eLiposomes (folated eLipoDox). Confocal images
showed that folate was required to accumulate a high concentration of eLipoDox inside the cell.
Fluorescence spectroscopy showed that an emulsion droplet significantly increased the release of
Dox from liposomes using ultrasound. Cell viability assays showed that folated eLipoDox was
significantly better at killing MDR KB cells than freely administered Dox. Folate attached to the
liposome, PFC5 emulsions inside of the liposome, and Dox loaded in the liposome were all
required to get the best killing of MDR KB cells. When folated eLipoDox was co-delivered with
verapamil, an export pump inhibitor, resistant and sensitive KB cell viability was reduced to
under 30%, which was significantly better than the killing of sensitive KB cells treated with free
Dox.
One significant, but unexpected, result was that ultrasound had a minimal effect on the
killing of KB cells treated with folated eLipoDox. We surmise, with some supporting evidence,
that the reason why so much killing occurred with folated eLipoDox without US was that the dox
crystals inside of the liposome provided nucleation sites for the PFC5, and vaporization caused
Dox release from the liposome at some time after the folated eLipoDox was endocytosed.

109

Despite ultrasound being unable to provide a means to externally trigger the release of
Dox from eLiposomes, folated eLiposomes were able to overcome the multidrug resistance of
KB-V1 cells. The effectiveness of eLiposomes to control the delivery of Dox to cancer cells is
dependent on the specificity of the targeting ligand. Folated eLipoDox could be endocytosed by
any cell that has a folate receptor. Many cancer cells overexpress folate receptors and therefore
folated eLipoDox has a greater probability of being endocytosed by such a cancer cell. Folated
eLipoDox provides an optimal drug delivery vehicle for delivering drugs directly to the cytosol,
which is more cytotoxic than conventional drug delivery.

9.2

Recommendations
In order to confirm that folated eLipoDox can preferentially target cancer cells that

overexpress folate receptors, folated eLipoDox can be delivered to a co-culture of cells in vitro
with one cell line that has a high expression of folated receptors and another cell line that has a
low expression of folate receptors. Folated eLipoDox is effective at releasing Dox to the cell
cytosol without ultrasound. The effectiveness of using folated eLipoDox in vivo will depend on
its ability to accumulate at the site of the tumor. Optimizing the size of the liposomes will help
them escape capture by the RES and allow them to escape any leaky vasculature at the tumor
site. A passive release mechanism is also beneficial in targeting metastatic sites, which are
located at unknown sites in the body.
Another possibility in future research is to make folated eLipoDox stable inside of the cell
until US is applied. Avenues to pursue include using different nucleating agents, such as PFCs
with higher normal BPs (e.g. perfluorooctane), and optimizing the drug to lipid ratio and the size
of the emulsion droplets and liposomes. Different drugs that do not form a fiber when loaded in
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liposomes might also be able to control the release using US. Previous experiments [9, 122]
showed calcein released from eLiposomes only when US was applied. Calcein was loaded in
liposomes passively when the liposomes were formed. This was not as efficient in loading as the
remote loading of Dox (pH gradient loading), meaning that more of the drug was wasted during
the loading process; but a different loading process might be able to allow for controlled release
using ultrasound.
Co-delivery of folated eLipoDox and verapamil was the most effective drug delivery
method for killing the MDR KB-V1 cells. However, the verapamil was not delivered inside of an
eLiposome. The stability and encapsulation efficiency of verapamil inside of eLiposomes should
be investigated. If verapamil cannot be delivered to the cytosol in a sufficient concentration,
other efflux pump inhibitors should be investigated to find an inhibitor that can be loaded in an
eLiposome and co-delivered with folated eLipoDox at sufficient concentrations to overcome
multidrug resistance.
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